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Abstract 
Upon infection, human adenovirus (HAdV) must block interferon signaling and activate 
the expression of its early genes to reprogram the cellular environment to support virus 
replication.  During the initial phase of infection, these processes are orchestrated by the 
first HAdV gene expressed during infection, early region 1A (E1A).  E1A binds and 
appropriates components of the cellular transcriptional machinery to modulate cellular 
gene transcription and activate viral early genes transcription.  We have identified 
hBre1/RNF20 as a novel target of E1A.  hBre1 is an E3 ubiquitin ligase which acts with 
the Ube2b E2 conjugase and accessory factors RNF40 and WAC1 to monoubiquitinate 
H2B at K120 (H2B-ub), a mark of chromatin which is highly transcriptionally active.  
hBre1 and the activity of the hBre1 complex to monoubiquitinate H2B, was found to be 
critical for interferon mediated induction of interferon stimulated genes (ISGs) and the 
establishment of an anti-viral state.  During infection, E1A targets hBre1 at ISG gene 
bodies and blocks the catalytic component of the hBre1 complex, Ube2b from being 
recruited to ISGs.  As a result, E1A can antagonize the innate antiviral response by 
blocking H2B monoubiquitination and, as such, ISG transcription.  In contrast to 
blocking hBre1 activity at ISGs, E1A is able to recruit hBre1 to viral chromatin where 
hBre1 participates in the transactivation of HAdV early genes.  As E1A blocks the 
catalytic activity of the hBre1 complex, E1A retasks hBre1, altering hBre1 function from 
an E3 conjugase to a scaffold which recruits the cellular transactivator, hPaf1.  hPaf1 is 
recruited by hBre1 and E1A to HAdV early genes to induce activating histone post-
translational modifications, H3K4 trimethylation and H3K79 trimethylation.  The ability 
of E1A to target hBre1 to simultaneously repress cellular IFN dependent transcription 
while activating viral transcription represents an elegant example of the incredible 
economy of action accomplished by a viral regulatory protein through a single protein 
interaction. 
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Prelude 
 
“In the beginning there was nothing, which exploded.” Terry Pratchet.   
 
This thesis is built on independent experiments that produced negative or confusing 
results which, for a long time, amounted to nothing understandable.  After a time (three 
years), all of these confusing results came together to form a coherent hypothesis and this 
lead to an explosive expansion of positive results and information.  All of the 
experiments that didn’t work or didn’t provide publishable information and are not 
displayed anywhere in this thesis were likely just as important as the data contained 
within.  In the end, displayed herein are a compendium of positive results and an accurate 
depiction of only what was discovered and not necessarily everything that was learned.  
What I have learned is largely represented by all of the mistakes I have made.   These 
have been ignored and are now only hearsay tales of the past on which my future is built.   
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Chapter 1:  Introduction 
1.1 General Introduction 
 Viruses, being obligate intracellular pathogens, are incapable of independent 
replication.  Instead, they must parasitize a host and subvert the host's cellular machinery 
to propagate.  As a result, viruses have coevolved with higher organisms and typically 
make a complex network of interactions within the host cell to reorganize the cellular 
milieu into an environment favourable for the production of viral progeny. Historically, 
studies of virus-host cell interactions have proven invaluable in helping scientists 
elucidate the mechanisms regulating complex cellular processes such as replication, 
transcription, and immune responses. 
 With respect to using viruses to learn about the cell, the study of Adenovirus 
(AdV) is no exception.  AdV has been used to study such processes as cell cycle control, 
DNA replication, transcription, mRNA processing, apoptosis and immunological 
responses (Shenk, 1996).  Originally identified in 1953 (Rowe et al., 1953), AdV are 
small non-enveloped viruses with a linear double stranded DNA genome of 
approximately 35 kilobase pairs (Figure 1.1).  The AdV family includes more than one 
hundred members infecting a range of species from mammalian to avian to reptilian.  In 
1954, human AdV (HAdV) was implicated as the causative agent for acute respiratory 
disorder (Hilleman and Werner, 1954).  Currently, there are 52 members of HAdV which 
are separated into 6 species, and a 7th proposed species, based on various criteria (Figure 
1.2) (Benkö et al., 2000; Jones et al., 2007).  Members of the HAdV family have evolved 
specific niches with wide organ tropism (including the respiratory system, intestinal 
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Figure 1.1.  A cartoon representation of the HAdV-5 double stranded DNA genome.  The 
HAdV-5 genome has ten transcriptional units, five of which are expressed early during 
infection: E1A, E1B, E2e, E3, and E4, two are expressed delayed early: IX and VARNA, 
and three late during infection; Late genes, E2L, and UXP. 
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digestive system, and blood) causing an array of clinical diseases in humans, although 
many infections are asymptomatic.  In 1962, HAdV type 12 was found to cause tumours 
in baby hamsters (Trentin et al., 1962).  This was the first example of a human virus 
inducing cancers.  Later, it was shown that HAdV 12 could induce tumours when injected 
into the retina of baboons (Mukai et al., 1980).  Although not all subgroups of HAdV are 
capable of causing tumours in rodents, all have been shown to transform rodent cells in 
tissue culture (Shenk, 1996).  Differences in tumorigenicity are attributed to differences 
in the ability of the various HAdV types to evade host immune responses, as types unable 
to induce tumours in immunocompetent rodents are capable of inducing tumours in 
immuno-compromised rodents (Gallimore, 1972). 
 
1.2 Adenovirus 
1.2.1 Physical properties of adenoviruses. 
Structurally, adenoviruses are comprised of a non-enveloped icosahedral protein shell 
that ranges in size between 60-90 nm depending on the species.  The icosoheral shell 
consists of 240 hexons and 12 pentons which make up the 252 subunits called 
capsomeres (Ginsberg et al., 1966).  As the names indicate, the pentons and hexons are 
surrounded by 5 or 6 other capsomeres respectively. The pentons form a base for a 
protruding fibre of a length which is HAdV type dependent (Norrby, 1966; Norrby and 
Skaaret, 1967).  The fibre knob in HAdV5 initially interacts with a host receptor, the 
coxsakievirus and adenovirus receptor (CAR) in HAdV5.  A subsequent interaction 
between the arginine-glycine-aspartic acid (RGD) motif in the penton base and cellular 
integrins (namely αv-β3 and αv-β5), allows HAdV to be taken up via phagocytosis
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Figure 1.2.  Classification schemes for HAdV.  HAdVs were originally separated into 6 
species based on several criteria including hemagglutination of erythrocytes and 
oncogenic potential both in vivo and in vitro.  Since then, genome sequencing of HAdVs 
has confirmed species classification and added a purported 7th species.  Figure adapted 
from Fundamental Virology, 3rd edition. 
AGroup Serotypes
Oncogenic Potential
Tumors in
animals
Transformation
in tissue culture
% of G-C in DNAHemagglutination
(little or no agglutination) 12,18,31 High + 48-49
B Moderate + 50-523,7,11,14,16
21,34,35,50
C Low or none + 57-591,2,5,6
complete agglutination
of monkey erythrocytes
partial agglutination
of rat erythrocytes
D Low or none + 57-618,9,10,13,15
17,19,20,22-30
32,33,36-39
42-49,51
complete agglutination
of rat erythrocytes
E Low or none + 57-594
F Unknown + 50-5140,41
G Unknown N/A 55.152
( )
( )
( )
6
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 (Meier and Greber, 2004).  It should be noted, however, that not all adenoviruses contain 
the integrin targeting RGD motif and exchange of this region will change specificity to 
cellular receptors (Wickham et al., 1995; Cuzange et al., 1994; Albinsson and Kidd, 
1999). 
 Held within the AdV capsid lies a linear double stranded DNA genome, ranging 
in size from 30-38 kbp, with a conserved organization throughout the HAdV family.  
Each end of the genome contains an inverted terminal repeat, which accounts for 103bp 
in HAdV5 (Steenbergh et al., 1977). The genome has arbitrarily been given 
directionality, with the left end of the genome containing a cis-acting packaging sequence 
located between 200-400bp that mediates interaction with the capsid proteins and 
encapsidation of the genome (Gräble and Hearing, 1992; Hearing and Shenk, 1983; 
Ostapchuk and Hearing, 2003).  The 5’ end of each DNA strand of the genome is 
connected via a phosphodiester bond on the terminal viral nucleotide to a serine residue 
within the 55kDa adenovirus terminal protein (TP) (Rekosh et al., 1977).  The TP 
functions as a primer during viral DNA replication, assists in viral packaging and has also 
been suggested to protect the virus from being recognized by DNA damage machinery as 
it covers the free ends of the linear viral genome (Weitzman and Ornelles, 2005; Stracker 
et al., 2002; Karen et al., 2009). Viral genes are encoded on both strands of the genome 
and can be separated into two classes: the early genes which are produced before the 
onset of viral genome replication and are involved in cellular restructuring for virus 
production, and the late genes which are produced after the onset of viral genome 
replication and include the structural proteins which make up the viral capsid (Figure 1.1) 
(Shenk, 1996).   
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1.2.2 Adenovirus transcripts.  
As explained earlier, after viral attachment via the knob of the fibre protein, 
internalization occurs through binding of the RGD sequence found in the penton base to 
αVβ3 and αVβ5 integrins (Williams et al., 1975; Varga et al., 1991).  This leads to 
receptor mediated endocytosis (Svensson, 1985).  Acidification of the endosome causes 
release of pentons and the partially disrupted virus particle escapes  to the cytosol through 
an, as yet, unknown mechanism (Mellman, 1992).  Throughout the transportation 
process, viral uncoating is progressing, leaving, at this point, the genome associated with 
hexon (Greber et al., 1993; Meier and Greber, 2004).  The viral genome is then 
transported to the nucleus by hexon using the cellular microtubule network.  (Lonberg-
Holm and Philipson, 1969; Philipson and Lonberg-Holm, 1969; Chardonnet and Dales, 
1972; Dales and Chardonnet, 1973).  Once the genome reaches the nucleus, the first gene 
transcribed is the early region 1A gene (E1A). Transcription of the other early genes 
follows closely after E1A and includes E1B, E2 early (E2e), E3, and E4.  Though some 
of the virus structural proteins, including terminal protein, are encoded in the E2 late 
(E2l) gene and UXP, the majority of structural proteins are encoded by the Major Late 
gene.  Many of the HAdV gene transcripts undergo extensive splicing, which 
substantially increases the number of possible protein products produced upon translation  
(Berget et al., 1977; Shenk, 1996).  In fact, the process of splicing was initially described 
using the HAdV Major Late gene transcript and led to a Nobel prize for Drs. Richard J. 
Roberts and Phillip A. Sharp in 1993. 
 The E1 region, which includes E1A (discussed at length later) and E1B, is 
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necessary for oncogenic transformation.  The E1B region encodes two proteins, both of 
which are anti-apoptotic, and are named for their observed molecular weights, 55kDa and 
19kDa. E1B-55k acts early in infection to inhibit the guardian of the genome, the p53 
tumour suppressor (Yew and Berk, 1992). Specifically, E1B-55k functions as a viral 
sumo ligase to modify p53, and force p53 nuclear export via an interaction with cellular 
PML (Muller and Dobner, 2008; Pennella et al., 2010). As well E1B-55k works in 
conjuction with the HAdV E4-ORF3 to sumoylate the Mre11-Rad50-Nbs1complex 
involved in DNA damage response (Stracker et al., 2002; Sohn and Hearing, 2012).  
E1B-55k also co-operates with E4-ORF6 during infection to recruit the Nxf1/Tap export 
receptor for the transport of late viral RNAs from the nucleus to the cytoplasm, where the 
cellular translation machinery is hijacked into making late viral protein products 
(Gonzalez and Flint, 2002; Flint and Gonzalez, 2003; Yatherajam et al., 2011).  Similarly 
to E1B-55k, E1B-19k works as an anti-apoptotic agent during infection. The E1B-19k 
protein is a viral mimic of Bcl2 which binds to BAX and blocks cytochrome c release 
from the mitochondria (Rao et al., 1992; Chiou et al., 1994; Farrow et al., 1995). 
 The E2 gene codes for three proteins that drive the replication of the viral 
genome.  E2 encoded genes include the terminal protein (discussed earlier), the 140 kDa 
DNA-dependent DNA polymerase and the 59 kDa single stranded DNA binding protein.  
These three proteins work together to support the replication of the viral DNA.  
Replication occurs 5’ to 3’ with the terminal protein acting as a protein primer covalently 
attached to deoxycytosine monophosphate (Kelly and Lechner, 1979). The DNA binding 
protein binds single stranded viral DNA intermediates and then acts in conjunction with 
the viral DNA-dependent DNA polymerase to replicate the viral genome (Van Breukelen 
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et al., 2003; van der Vliet and Levine, 1973; Van Der Vliet et al., 1975; Levine et al., 
1976; Challberg and Kelly, 1979a, 1979b; Challberg et al., 1980; Challberg and Kelly, 
1981). 
 The E3 region contains one differentially spliced transcript which codes for 6 
known protein products. These products are all seemingly involved in promoting cell 
survival, for the most part by antagonizing adaptive immune activity.  These include 
Receptor internalization and degradation αβ (RIDαβ), gp19K, 14.7K, 12.5K, and 6.7K 
While the adenovirus death protein (ADP) is involved in cell lysis. RIDαβ dimers are O-
linked oligosaccharide modified intracellular plasma membrane linked proteins.  From 
the plasma membrane and in conjuction with other E3 gene products, RIDαβ is involved 
in blocking extrinsic death ligand signals triggered by TNF (tumour necrosis factor) 
(Benedict and Ware, 2001; Friedman and Horwitz, 2002), Fas (TNF superfamily, 
member 6) ligand (Shisler et al., 1997; Elsing and Burgert, 1998; Tollefson et al., 1998), 
and TRAIL (TNF-related apoptosis-inducing ligand) (Tollefson et al., 2001). This is 
achieved through destruction of proapoptotic receptors, and blocking of TNF-mediated 
arachidonic acid release and NF-κB (nuclear factor kappa-light-chain-enhancer of 
activated B cells) activation (Friedman and Horwitz, 2002). gp19K is a transmembrane 
protein localized to the endoplasmic reticulum (Hermiston et al., 1993a, 1993b).  It acts 
to obstruct CTL-mediated killing via blocking tapasin-mediated complex formation of 
MHC-class I molecules and this blocks the subsequent expression of MHC class I/antigen 
complexes on the cell surface (Bennett et al., 1999).  14.7K is the only known soluble E3 
protein and is involved in binding and inhibiting the apoptotic activity of TNF, NF-κB 
and Caspase 8 (Klingseisen et al., 2012; Krajcsi et al., 1996).  E3 6.7K is also a 
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transmembrane protein which acts in conjuction with RIDαβ in the downregulation of 
TRAIL and TNF signaling via blocking arachidonic acid release (Benedict and Ware, 
2001; Moise et al., 2002). ADP is a transmembrane protein which, contrary to the rest of 
the E3 genes, is proapoptotic and also is predominantly expressed late during infection 
(Tollefson et al., 1992). ADP functions through an as yet unknown mechanism with 
MAD2B (Mitotic spindle assembly checkpoint protein) in viral lysis of infected cells 
(Ying and Wold, 2003). Despite much study of the E3 proteins, the 12.5K protein has no 
known function and is not required for virus replication.  Interestingly, E3 12.5K is 
highly conserved throughout HAdV types suggesting that it serves and evolutionarily 
important function (Hawkins and Wold, 1992). 
 The E4 mRNA is differentially spliced to encode 7 potential protein products, 5 of 
which have known functions.  Of the possible products, E4 open reading frame (orf ) 2 
has no known activity and E4orf3/4 has not been detected during infection.  Mutant virus 
in which these orfs are deleted do not display even weak growth defects.  E4orf1 is only 
detected in HAdV subgroup D viruses 9 and 26 (Javier, 1994; Weiss et al., 1997).  
Despite the low conservation of expression, E4orf1 shows a very pronounced phenotype.  
E4orf1 is the critical oncogenic determinant in the ability of subgroup D viruses to elicit 
mammary tumours in rodents (Thomas et al., 2001; Chung et al., 2007).  This occurs via 
an interaction with cellular PDZ proteins MUPP1, MAGI-1, ZO-2, and Dlg1 through an 
unknown mechanism (Chung et al., 2007).  E4orf3 is highly conserved both 
immunologically and by sequence comparison.  The E4orf3 protein forms a unique 
nuclear polymer, which partitions off the nucleus into various compartments (Ou et al., 
2012; Sarnow et al., 1982).  This viral polymer is then able to inactivate multiple tumour 
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suppressors including p53, PML, TRIM24, interferon response and, in conjunction with 
E1B-55k as noted above, the MRN DNA damage complex (MRE11/RAD50/NBS1) 
(Ullman et al., 2007; Ou et al., 2012; Stracker et al., 2002; Sohn and Hearing, 2012).  The 
E4orf4 protein binds and retargets the global cellular phosphatase PP2A.  E4orf4 
retargeting of PP2A induces p53 dependent cell death which may be important in virus 
release (Brestovitsky et al., 2012; Branton and Roopchand, 2001).  As well, PP2A is 
redirected by E4orf4 to regulate alternative splicing of late genes through altering the 
phosphorylation of the cellular alternate splicing factor SR proteins (Kanopka et al., 
1998; Estmer Nilsson et al., 2001).  As previously mentioned, E4orf6 forms a 
multifunctional complex with E1B-55k.  This drives viral DNA replication, RNA 
processing, and nucleo-cytoplasmic transport of late viral mRNAs.  This complex also 
blocks host protein synthesis via prevention of cellular mRNA transport from the nucleus 
(Halbert et al., 1985; Huang and Hearing, 1989; Yatherajam et al., 2011; Bridge and 
Ketner, 1990).  As well, both E4orf3 and orf6 are responsible for preventing 
concatamerization of the HAdV genome by DNA ligase IV   (Weiden and Ginsberg, 
1994; Baker et al., 2007). Lastly, the E4orf6/7 protein is involved in activation of cell 
cycle programming and HAdV E2 transcription via binding and redirection of dimers of 
the cellular E2F transcription factor, which is freed up by dissociation from pRb by E1A 
(Huang and Hearing, 1989; Cress and Nevins, 1994; Hardy et al., 1989; Reichel et al., 
1989; Cress and Nevins, 1996; Helin and Harlow, 1994). 
 The Major Late transcript is differentially spliced and, along with U-exon protein 
(UXP) and the E2l genes, codes for the structural and non-structural proteins which are  
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Figure 1.3.  Diagrammatic representation of E1A splice products.  (A) The E1A transcript 
is differentially spliced into 5 products.  Blocks represent the exons while lines represent 
introns.  All spice events maintain the translational reading frame except in the 9S 
encoded product ,which changes reading frame due to splicing and this is denoted by 
crosshatching.  (B) Cartoon of the E1A protein products aligned to sequence expression 
as a result of the splicing events.  Conserved regions (CR) 1-4 are labeled and denoted by 
orange, pink, blue, and yellow boxes, respectively.  The novel sequence in the 55R 
protein produced by the 9S mRNA is denoted by crosshatching. 
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involved in virion assembly and packaging (Tollefson et al., 2007; Shenk, 1996).  The 
virus is assembled in the nucleus and the cell is eventually lysed via several mechanisms 
including ADP production, releasing approximately 10,000 infectious virions per cell. 
 
1.3 HAdV early region 1A (E1A) 
1.2.3 Human adenovirus early region 1A (E1A).  
The first gene expressed during infection is E1A.  E1A is found at the extreme left end of 
the genome (Figure 1.1) (Nevins et al., 1979).  The E1A genes are responsible for 
establishing a favourable environment for the replication of virus.  During infection, E1A 
activities include modulating host cell transcription, such as in inducing quiescent 
epithelial cells to enter S-phase, and activating the transcription of the other viral early 
genes.  The E1A transcript is differentially spliced into 5 variant products (Figure 1.3).  
The two largest mRNA products, 13S and 12S, are the major early splice products.  They 
encode 289 and 243 residue E1A proteins in HAdV5, and these differ only by a 46 amino 
acid sequence that is unique to the larger protein (Figure 1.3).  These early proteins 
display a predominantly nuclear or nucleocytoplasmic localization (Rowe et al., 1983; 
Turnell et al., 2000).  Later during infection, a shift in splice site preference increases 
production of the 11S, 10S and 9S E1A mRNA species, which encode proteins of 217, 
171, and 55 residues respectively in HAdV5 (Stephens and Harlow, 1987; Ulfendahl et 
al., 1987).  All splicing events in E1A preserve the reading frame except in the 9S 
product, which contains a unique 29 amino acid sequence at its C-terminus (Figure 1.3).  
Comparisons of the sequences of the largest E1A proteins from different AdV types 
identified four regions of high conservation, termed Conserved Region (CR) 1 through 4  
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Figure 1.4. Map of E1A conserved regions (CR) and the location of selected linear 
interaction motifs (LIM).  Selected short linear protein interaction motifs that have been 
identified within E1A are shown. The E1A sequence and the sequences of other viral and 
cellular proteins that also use this LIM for interaction with the target protein are also 
indicated. Sequence shading indicates consensus with the indicated LIM. Figure adapted 
from Pelka et. al., 2008. 
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(Figure 1.4) (Kimelman et al., 1985; van Ormondt and Hesper, 1983; Avvakumov et al., 
2002, 2004).  The conservation of these sequences suggests that their functions are 
critical for the viral life cycle.  
 
1.3.1 E1A is an unstructured protein which contains numerous discrete protein-
protein interaction motifs.   
E1A is able to act without any enzymatic or specific DNA binding capacities.  Instead, 
E1A functions through the interaction and sequestration of key cellular factors and 
redirects the activity of these proteins to advance the infectious cycle.   The promiscuous 
nature of the E1A protein interactions leads to a multitude of different effects, which 
virtually reprogram the entire regulatory circuitry of the host cell.  To date, there has been 
neither a successful crystal nor solution structure for the full E1A protein.  This is thought 
to be a result of the lack of intrinsic structure in the E1A protein.  Indeed, programs such 
as PONDR (Garner et al., 1999; Romero et al., 2001), which determine the likely nature 
of tertiary protein structure, predict that E1A is almost entirely unstructured (Figure 1.5) 
(Pelka et al., 2008).  This is not wholly unexpected, as many cellular proteins that interact 
with large numbers of target proteins are also largely unstructured (Dunker et al., 2005; 
Kim et al., 2008).  This lack of intrinsic structure allows this class of proteins to bind 
many unrelated proteins through the use of short linear interaction motifs (LIMs) (Figure 
1.4).  LIMs can adopt multiple alternative conformations, increasing their ability to bind 
dissimilar targets (Dunker et al., 2005).  The E1A proteins appears to utilize this strategy 
to excess; being effectively comprised of a string of LIMs that interact with many 
different types of proteins, including kinases, transcriptional activators and repressors, 
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Figure 1.5. Alignment of selected HAdV E1A proteins and prediction of intrinsic 
disorder.  The amino acid sequences of the largest E1A proteins of HAdV-3, 4, 5, 9, 12 
and 40, which represent members of each of the six HAdV subgroups, are shaded with 
respect to their predicted preference to form intrinsically unstructured regions (black) or 
structured domains (unshaded). The conserved regions (CR1-4) are indicated and 
sequences are aligned based on amino acid similarity. Figure adapted from Pelka et. al. 
2008. 
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and cell cycle regulators (Pelka et al., 2008).  It is believed that each separate binding 
motif within this viral protein may exhibit local and specific structure when interacting 
with a specific target protein as is seen with the interaction between E1A and the TAZ 
domain of p300 or in the case of a segment of the C-terminus of HAdV  12 E1A and 
CtBP (C-terminal binding protein) (Ferreon et al., 2009; Molloy et al., 2000).  This, 
coupled with the high expression level of E1A protein during infection, aids this viral 
protein in interacting with a plethora of cellular proteins.  This strategy leads to the 
greatest possible effect on the cellular protein network from the smallest allocation of 
viral coding capacity.  Further, this characteristic of  the E1A protein makes it ideal for 
mutational analysis, as insertions and deletions typically only affect processes dependent 
upon the specific LIMs that are perturbed in the targeted area, rather than having more 
global effects on E1A function via alterations in folding (Bayley and Mymryk, 1994).  
Furthermore, portions of the E1A protein still maintain their individual activities when 
they are subdivided into segments or modules (Bayley and Mymryk, 1994).  This allows 
a complex protein, which normally disrupts a substantial number of cellular pathways 
through a plethora of different interactions, to be segmented into smaller portions that can 
be more easily studied in isolation. 
 
1.3.2 E1A is a modulator of cellular hub proteins and is itself a viral hub.  
E1A is indispensable for productive HAdV replication at a physiologically relevant 
multiplicity of infection (MOI) (Jones and Shenk, 1979) as it is required for the earliest 
stages of viral infection.  Not surprisingly, the primary function of E1A is to initiate the 
viral replication cycle. This is achieved in two ways: by activating the transcription of 
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Figure 1.6. Model of IFN signalling in response to virus infection.  Cellular receptors 
recognize virus upon entry into the cell and respond via downstream phosphorylation of 
IRF3.  Upon phosphorylation IRF3 dimerizes and activates the transcription of genes 
required for anti-viral effects, including IFNβ1.  IFNβ1 is then secreted into the 
extracellular matrix where it can act in an either autocrine or paracrine mode to activate 
the IFNβ receptor.  The IFNβ receptor activates the TYK2 and JAK1 kinases which act to 
phosphorylate STAT1 and STAT2.  Upon phosphorylation, STAT1 and STAT2 form a 
heterodimer and complex with IRF9 (called the ISGF3 complex).  ISGF3, along with 
other factors, then activates transcription of >300 cellular genes. 
S
T
A
T
1
IRF3
?
IFNβ
S
T
A
T
1
IRF9
S
T
A
T
2 PP
S
T
A
T
2
IFNβ
TYK1 JAK1
IRF9
P
IRF3
IRF3
P
ISRE
IFNβ1 promoter
23
24 
 
other viral early genes and by altering the host cell environment via transcriptional 
modulation of host cell gene expression to create an environment favouring viral 
replication (Bayley and Mymryk, 1994; Gallimore and Turnell, 2001; Flint and Shenk, 
1989).  Of important note, E1A is recruited to more than 17,000 host cell promoters 
during infection and modulates the transcription of many of these (Horwitz et al., 2008b; 
Ferrari et al., 2008).  To accomplish this, the relatively small 289 residue E1A protein 
must make the most of its interactions with the host cell protein interaction network.  The 
most economical means by which the virus can achieve this is to target proteins which 
themselves have many cellular interactions, and therefore, modulate many cellular 
processes.  Such proteins are known as cellular hub proteins, as they make multiple 
connections with the cell protein interaction network and function as critical regulators of 
cellular processes and activities (Batada et al., 2006; Haynes et al., 2006).  These include 
proteins such as the G1 checkpoint protein pRb, the general cellular transcriptional 
activator p300/CBP, and the cellular repressor CtBP; all of which are targets of the E1A 
protein (Pelka et al., 2008).  For example, pRb functions as a key regulator of the G1-S 
phase transition, as well as a modulator of cellular replication, angiogenesis, transcription 
and chromatin structure (Talluri and Dick, 2012).  By targeting cellular hub proteins such 
as pRb, the relatively small E1A protein may affect a maximum number of pathways 
with a minimum number of interactions.  As a result of this property, studies of E1A have 
been an invaluable tool to study these important cellular regulatory hub proteins and the 
pathways they control. 
 
1.3.3 Depending on context, E1A can function as an oncogene or a tumour 
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suppressor.  
The strategy of targeting cellular hub proteins is not exclusive to viral proteins such as 
E1A.  Rather, this same result is seen in cancers, in which specific cellular hub proteins 
are repeatedly found to be affected.  In fact, viral hub oncoproteins such as E1A target the 
same proteins found affected in cancers with striking conservation.  These viral 
oncoproteins have been shown to predict cellular proteins involved in cancer with a 
reliability as great or greater than other approaches (Rozenblatt-Rosen et al., 2012).  
With respect to cancer, the typical HAdV infection ends with lysis of the host cell 
and the release of progeny virus.  Cell death precludes the possibility of malignancies 
resulting from human infection.  As such, HAdVs are not generally thought to be a cause 
of human cancer.  However, E1A is capable of immortalizing cells when introduced by 
stable transfection (Graham et al., 1977; Whittaker et al., 1984).  This is indeed the case 
for the commonly used Human Embryonic Kidney (HEK) 293 cell line, which was 
transformed by the stable transfection of the left end of the HAdV genome expressing 
both the E1A and E1B oncogenes (Whittaker et al., 1984).  Despite this, transformation 
of human cells with the HAdV genome is difficult and unreliable.  Further, HAdV is not 
seen as a causative agent in cancers like other DNA tumour viruses, including human 
papillomavirus and polyomavirus.  
In contrast, infection of immunocompromised rodents with HAdVs can cause 
aggressive and malignant tumors (Trentin et al., 1962).  As well, rodent cells are readily 
immortalized by E1A and fully transformed in cooperation with a second oncogene, such 
as E1B or activated Ras (Bayley and Mymryk, 1994; Gallimore and Turnell, 2001; Flint 
and Shenk, 1989). In part, this difference is due to the fact that HAdV infections are non-
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productive in rodents.  Infected cells are not killed during the virus replication cycle due 
to a deficiency in viral DNA replication and late viral protein production (Eggerding and 
Pierce, 1986).  However, this does not explain the difficulty in transforming human cells 
with pieces of the HAdV genome (mainly E1A and E1B) and would seem to suggest that 
E1A is unable to modulate a cellular process in human cells which it either can affect, or 
is already primed for transformation in rodents.  This small evolutionary variation may be 
the key difference between HAdV, a very common infectious agent, causing or not 
causing cancer in humans. This question may be the next exciting avenue of research in 
the HAdV field.  Nevertheless, in the context of rodents, the oncogenic potential of the 
E1A protein is readily apparent.   
Paradoxically to the oncogenic effects of E1A on non-transformed cells, 
expression of E1A in previously transformed cell lines suppresses oncogenic phenotypes.  
This is seen with reductions in metastasis, angiogenesis and tumorigenicity in vivo, a 
triggering of apoptosis, and induction of a phenotypic mesenchymal to epithelial 
transition; the opposite phenotypic cellular change from what is seen in cancers (Deng et 
al., 2002; Mymryk, 1996; Frisch and Mymryk, 2002).  Thus, it is clear that E1A has 
multiple functions and that these influence many vital cellular processes.  By using E1A 
as a tool to study these processes, we may better understand the mechanisms by which 
they are normally regulated in a cell, as well as understand how viruses and cancers 
subvert them. 
 
1.3.4 E1A as a tool for identifying cellular regulatory proteins.   
E1A has an impressive track record as a tool for discovering and studying novel host 
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regulatory proteins.  The proteins initially identified via their interaction with E1A have 
been shown to be important in critical cellular processes such as cell cycle control and 
transcriptional regulation, further confirming the hub targeting strategy of E1A (Pelka et 
al., 2008).  As a viral hub protein, E1A will reorganize cellular protein interaction 
networks and divert their activity for the benefit of viral reproduction.  Overall, the E1A 
proteins have been found to interact with over 50 different cellular proteins, all of which 
likely influence vital cellular processes (Pelka et al., 2008).  As one example, the 
interaction between E1A and pRb was the first example of an oncoprotein interacting 
with a tumour-suppressor (Whyte et al., 1988).  In this case, E1A uses two distinct 
binding sites to displace the E2F family of proteins from pRb and block further 
association (Whyte et al., 1988; Fattaey et al., 1993).  The release of E2Fs from pRb has 
two distinct benefits for HAdV.   Firstly, E2F proteins are freed to allow transcriptional 
activation of viral genes.  Indeed, E2Fs derive their name from their initial identification 
as regulators of HAdV E2e transcription (Reichel et al., 1987).  Secondly, the release of 
E2F proteins allows E2F family members to activate E2F responsive cellular genes, 
including cyclin A and cdc2 (Pagano et al., 1992), which control S-phase entry (Ghosh 
and Harter, 2003).  However, the interaction of E1A with pRb is by no means the only 
manner in which E1A proteins affect cell cycle, as E1A mutants that are unable to bind 
pRb are still able to induce S-phase entry and activate viral early gene expression (Bayley 
and Mymryk, 1994; Gallimore and Turnell, 2001; Flint and Shenk, 1989; Frisch and 
Mymryk, 2002).  This indicates that other cellular targets of E1A can also influence this 
key pathway. 
 E1A also has direct effects on transcription through the binding of cellular 
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transcription factors, such as p300/CBP.  Rather than relieving the repressive effects on a 
transcription factor, such as the case of pRb,  E1A directly binds the p300/CBP 
acetyltransferases to activate transcription (Eckner et al., 1994).  This interaction was 
originally shown in the N-terminus/CR1 region where it is absolutely required for E1A 
dependent transcriptional activation, as well as E1A induced cellular transformation 
(Wang et al., 1993).  Our lab has recently published a novel direct interaction between 
p300/CBP and the CR3 portion of E1A, which along with the N-terminus/CR1 region, 
make up the two independent transcriptional activation domains within E1A (Pelka et al., 
2009b).  Interestingly, depletion of p300 in serum starved breast cancer cells causes these 
cells to divide (Kolli et al., 2001), whereas the interactions with pRb and p300/CBP are 
required by E1A to force baby rat kidney cells through the mitotic phase of the cell cycle 
(Jelsma et al., 1989; Howe and Bayley, 1992).  This difference may be explained by the 
discovery that E1A reorganizes p300/CBP on the cellular chromatin, removing it from 
promoters of genes involved in differentiation and targeting it to promoters involved in 
cell cycle (Horwitz et al., 2008b; Ferrari et al., 2008). Differentiation and cell cycle 
programming are opposing processes within the cell; as such, removing an activator of 
differentiation and transferring it to induce cell cycle promoters may have similar effects. 
Despite these advances, the role played by p300/CBP in E1A mediated transcriptional 
activation is still largely unknown.  
E1A also interacts with a well characterized transcriptional repressor, CtBP, 
through CR4 in the C-terminus of E1A (Chinnadurai, 2002).  In fact, CtBP was first 
discovered as an E1A interacting protein (Boyd et al., 1993).  The interaction between 
E1A and CtBP was shown to sequester CtBP from sequence specific DNA binding 
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factors, relieving transcriptional repression at specific cellular genes (Chinnadurai, 2002).  
This interaction is absolutely necessary to initiate the mesenchymal to epithelial 
transition induced by E1A and contributes to the ability of E1A to block tumourogenesis 
and metastasis (Boyd et al., 1993).  More recently, our lab in conjunction with the lab of 
Dr. R. Grand has shown a second independent interaction with CtBP which maps within 
the CR3 region (Bruton et al., 2008).  This interaction can direct the transcriptionally 
active CR3 region of E1A to CtBP occupied promoters, relieving CtBP mediated 
repression and then further activating these promoters (Bruton et al., 2008).  To the best 
of our knowledge, this may have been the first evidence of a viral protein exploiting a 
transcriptional repressor as a means of targeting specific promoters for activation. 
 The interactions of E1A with mammalian cellular proteins and the consequences 
of these interactions have been widely exploited and were critical in defining the role of 
many regulatory proteins within the cell.  As well, the E1A protein has been heavily used 
to study the requirements of transcriptional activation and transformation of cells.  Ergo, 
discovering novel interactions with E1A may identify proteins important in vital cellular 
processes and provide mechanistic insight into their activities. 
 
1.3.5 E1A activates viral transcription.  
The study of how E1A activates viral transcription has greatly increased our knowledge 
of cellular transcription activation complexes.  In the late 1970’s, it was shown that the 
largest product of the E1A gene, 289R in HAdV5, was able to activate transcription. This 
was shown to require the region later deemed CR3 (Harrison et al., 1977; Berk et al., 
1979).  E1A CR3 is necessary to activate transcription from the viral genome, although it 
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is not alone sufficient as CR3 activates at a much reduced potency (Culp et al., 1988; 
Bayley and Mymryk, 1994; Berk, 2005; Flint and Shenk, 1997; Gallimore and Turnell, 
2001; Ablack et al., 2010).  Interestingly, unlike most of the E1A protein, CR3 does not 
appear to be intrinsically disordered (Garner et al., 1999; Romero et al., 2001).  
Considering this, it is not surprising that CR3 does not tolerate deletion mutants or 
contain short linear interaction motifs like the rest of the E1A protein (Egan et al., 1988; 
Fahnestock and Lewis, 1989; Pelka et al., 2008) (Figure 1.4).  Indeed, CR3 is predicted to 
have defined tertiary structure coordinated by a novel zinc finger (Culp et al., 1988; Pelka 
et al., 2008). This may suggest that the purpose of this region is specifically defined for a 
single role; to be a stable scaffold for the recruitment of factors necessary for 
transcriptional activation.  Consistent with this hypothesis, the zinc finger domain of CR3 
was shown to interact with TBP and a component of the mediator adaptor complex, 
MED23 (Geisberg et al., 1994; Boyer et al., 1999; Stevens et al., 2002; Webster and 
Ricciardi, 1991).  With these interactions, CR3 is able to recruit transcriptional activation 
complexes which are essential for E1A dependent virus early gene transcription.  Further, 
the adjacent auxillary region 1 (AR1) region is necessary for activation of virus early 
genes through an as yet undefined means (Ström et al., 1998). CR3 recruits many 
additional factors for modulation of transcription.  These include coactivators of CR3 
dependent transcription, SUG1 and p300 (Rasti et al., 2006; Pelka et al., 2009b).  As 
well, CR3 recruits repressors of CR3 mediated transcription, including GCN5 and BS69, 
presumably to allow for tight controls on transcriptional activation to maximize virus 
replication (Ablack et al., 2010; Hateboer et al., 1995; Masselink and Bernards, 2000). 
Overall, the structural components and mechanistic insight into CR3 function are fairly 
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well defined.  However, as mentioned above, CR3 is necessary but not sufficient for 
transcriptional activation of early viral genes.  Indeed, effective recruitment of p300/CBP 
to viral promoters requires the N-terminal region of E1A (Pelka et al., 2009b).  In fact the 
N-terminal region of E1A, though unable to directly activate viral gene expression alone, 
is essential for optimal viral early gene transactivation in conjunction with CR3 
(Duyndam et al., 1996; Wong and Ziff, 1994).  Despite interacting with a plethora of 
known transactivators (AP2, TRAAP, TR, p300/CBP, p400, pCAF, and TBP, to name a 
few) (Pelka et al., 2008; Frisch and Mymryk, 2002), the mechanism by which the N-
terminus of E1A participates in E1A dependent transcriptional activation of HAdV early 
genes is still not fully understood.  
 
1.3.6 E1A modulates cellular transcription.  
In 2008, two papers published in Science helped bring to light the global breadth with 
which E1A affects host cell transcription (Horwitz et al., 2008b; Ferrari et al., 2008). It 
was found that E1A is bound to the regulatory region of more than 17,000 host cell 
genes.  Further, E1A modulates the expression of the host cell transcriptome by 
activating and repressing the expression of many of these genes.  This is done by 
recruitment of either transcriptional activating complexes such as p300 (Horwitz et al., 
2008b; Ferrari et al., 2008) or via recruitment of transcriptional repressor such as CtBP 
and pRb to promoter proximal regions (Sundqvist et al., 2001; Boyd et al., 1993; Ferrari 
et al., 2008; Whyte et al., 1989).  However, E1A modulation of expression from the host 
cell genome is far more complex.  In some circumstances, rather than recruiting these 
proteins to sites of active transcription to repress genes, E1A may use genes such as CtBP 
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and pRb to be recruit itself to sites of transcriptional repression.  Upon recruitment, E1A 
may then direct transcriptional activation complexes to these previously repressed genes 
to initiate transcription (Bruton et al., 2008; Ferrari et al., 2008, 2009).  Similarly, E1A 
uses transcriptional activators, such as p300, to recruit itself to the sites of 
transcriptionally active genes and repress transcription through the recruitment of 
repressor complexes (Pelka et al., 2009b; Ferrari et al., 2008, 2009). This adds many 
levels of complexity to the modulation of host cell gene expression by E1A, which allows 
this one viral protein to have a variety of effects on host cell transcription.  Interestingly, 
3 classes of genes may be found during adenovirus infection as seen in Ferrari et al., 
2008: Class I genes which are shut off early in infection and include genes involved in 
pathogen response and inflammation, Class 2 genes which are activated early in infection 
and are involved in cell growth, division and DNA synthesis, and Class 3 genes which 
are repressed at later times during infection and are involved in development and 
differentiation (Ferrari et al., 2008). These results globally confirm the current working 
model of E1A in reprogramming the infected cell.  Specifically, E1A blocks innate 
immunity, induces cell cycle and blocks/reverses differentiation. The net effect is that 
E1A optimizes the host cell environment for virus replication.  However, despite a large 
compendium of published data, the means by which E1A distinguishes each class of 
targeted gene is not well understood. 
 
1.3.7 E1A modulates the host immune system.  
Class 1 genes, including genes involved in innate immunity, are of special interest during 
the early stages of infection.  Innate immunity is the first line of defense against virus 
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infection. This is primarily mediated by TLRs (Toll-like receptors).  TLRs recognize 
pathogen-associated molecular profiles (PAMPS), such as lipopolysaccharide from 
Gram-negative bacteria in the case of TLR4 or non-methylated CpGs in foreign DNA as 
in the case of TLR9.  Recognition of viral infection by TLRs results in activation of type 
I (α and β) interferon (IFN) signaling (Hertzog et al., 2003; Stetson and Medzhitov, 
2006b).  Upon detection of foreign viral material, such as non-methylated DNA by TLR9 
(Hemmi et al., 2000; Krug et al., 2001; Latz et al., 2004), cells activate the IRF3 and NF-
κB transcription factors (Stetson and Medzhitov, 2006a).  This, in turn, results in the 
transcriptional activation of several antiviral genes including IFNs α and β (Stetson and 
Medzhitov, 2006b; Perry et al., 2005).  Upon secretion, IFNs may act as autocrine or 
paracrine ligands on the heterodimeric interferon αβ receptor (IFNαβR) (Raziuddin et al., 
1984; Schwabe et al., 1988).  Activation of the IFNαβ then leads to phosphorylation and 
activation of JAK1 and TYK2 which in turn leads to phosphorylation of the 
STAT1/STAT2 heterodimer (Kumar et al., 1994; Beadling et al., 1994).  Upon 
phosphorylation and dimerization of active STAT1/2 and subsequent recruitment of the 
transcription factor IRF9 (interferon regulatory factor 9) (altogether denoted the 
interferon stimulated gene factor 3 [ISGF3]) (Levy et al., 1989; Fu et al., 1990).  ISGF3 
then binds at interferon stimulated response elements (ISRE) and activates transcription 
of hundreds of cellular interferon stimulated genes (ISGs) (Figure 1.6) (Levy et al., 
1989). The combined expression of these ISGs results in the generation of an altered cell 
state that resists infection.  As one example, PKR (protein kinase R) recognizes double 
stranded RNAs commonly present during viral infection and phosphorylates eIF-2alpha 
to inhibit new protein synthesis (Galabru et al., 1989). To successfully replicate, viruses 
34 
 
must evolve mechanisms to evade the innate immune system and the interferon response 
or face extinction by natural selection. Some viruses, such as VSV (vesicular stomatitis 
virus) and SARS (severe acute respiratory syndrome) replicate at a fast rate which 
overloads the endoplasmic reticulum and blocks IFN secretion, thereby evading this 
response by brute force.  Most viruses have, however, required the evolution of specific 
mechanisms to block the IFN response.  Some viruses have evolved receptor mimics to 
outcompete IFN ligand, such as vaccinia virus. Marburg virus, polyomavirus and human 
cytomegalovirus (HCMV)  have evolved to block JAK1 activation, while EBV (Epstein-
Barr virus), JEV (Japanese encephalitis virus), HPV (human papillomavirus), myxoma 
virus, hepatitis D and possibly dengue have evolved to block TYK2 activation. Further, a 
lengthy and growing list of viruses affecting STAT1/STAT2 activation and dimerization 
includes HRSV (human respiratory syncytial virus), dengue, SV5 (simian virus 5), 
measles, mumps, hPIV2 (human parainfluenza viruses), sendai, hepatitis C, nipah virus, 
west nile virus, vaccinia virus, rabies, HPV, reovirus and, importantly for this work, 
HAdV (Taylor and Mossman, 2012; Galligan et al., 2006; Perry et al., 2005; Sadler and 
Williams, 2008).  
 HAdV particles were initially discovered to induce IFN in chick cells and in vivo 
by two distinct groups in the late 1960’s (Ho and Köhler, 1967; Béládi and Pusztai, 1967; 
Pusztai et al., 1969). It was initially believed that differential induction of the IFN 
response by different HAdVs was a result of differences in the viral capsid (Tóth et al., 
1983). Later, HAdV was found to specifically reduce MHC class-I antigens on the cell 
surface through HAdV E3-gp19K, resulting in a reduced sensitivity to IFN in vivo (Grand 
et al., 1987; Lichtenstein et al., 2004). Three years later, HAdV was shown to have 
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specific mechanisms for blocking the functions of specific ISGs. The viral VA RNA I 
blocks PKR activity through direct interference (Clarke et al., 1994; Ghadge et al., 1994; 
Katze et al., 1987; Kitajewski et al., 1986; O’Malley et al., 1989). In 1988, the lab of Dr. 
Darnell, through mutagenesis of the adenovirus genome, discovered that E1A specifically 
blocks IFN signaling in infected cells (Reich et al., 1988). This effect was later mapped to 
the N-terminus of E1A and shown to modulate transcriptional activation of IFN target 
genes (Kalvakolanu et al., 1991; Anderson and Fennie, 1987).  The data was suggestive 
of changes in histone modifications being the means by which transcription of IFN target 
genes was affected.  Interestingly, though most HAdVs modulate IFN sensitivity and 
transcriptional targets, some, such as HAdV 12, do not (Gallagher and Khoobyarian, 
1972, 1969; Béládi et al., 1973; Tóth et al., 1983; Zhao et al., 2009).  In the case of 
HAdV 12, the viral life cycle and replication progress much slower with lower viral titres 
at the end stage of infection (Zhao et al., 2009).  This may result from antagonism by the 
increased IFN signaling due to the inability of this virus to block IFN target gene 
transcription. 
 
1.4 Histone post-translational modifications (hPTMs) regulate gene expression.  
Eukaryotic DNA is compacted into a highly order structure called chromatin.  Chromatin 
is made up of structures known as nucleosomes.  The nucleosome is the basic unit of 
chromatin, consisting of approximately 146 nucleotides of DNA wrapped around a 
positively charged protein core containing 2 copies each of histone 2A, 2B, 3 and 4 and 
separated by free linker DNA of up to 80 bp.  Along with functioning in DNA 
compaction, the histones may be covalently modified with a set of moieties, called 
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histone post-translational modifications (hPTM), to signal the compaction of specific 
regions of DNA into euchromatin or heterochromatin.  While heterochromatin is highly 
correlated with transcriptional silencing, euchromatin regions may be transcriptionally 
active in the presence of transcriptional initiation complexes (Chi et al., 2010).  Further, 
condensation of DNA into chromatin is not static and the cell uses a large and complex 
array of machinery to modify and remodel chromatin (Chi et al., 2010; Jenuwein and 
Allis, 2001). 
 hPTMs are chromatin modifications in which moieties are covalently attached to 
the histones.  These include phosphorylation, acetylation, citrullination, 
monoubiquitinylation, sumoylation, and mono, di, and tri-methylation.  These moieties 
then either sterically alter the compaction of the chromatin, usually by modifications on 
the histone bodies, or signal the cell to alter chromatin compaction, usually through 
modifications on the histone tails (Chi et al., 2010).  hPTMs, altogether called the histone 
code, are a key mechanism by which cells interpret and adjust the transcriptional state of 
the underlying chromatin (Jenuwein and Allis, 2001). The combinatorial makeup of the 
modifications, rather than any one particular modifications assists in the physical and 
transcriptional end state of the affected gene. As such, although changes to a single 
modification can have drastic effects on the transcriptional state of a gene, this effect may 
differ depending on the remaining chromatin modifications.  For example, though H3K4 
trimethylation and H3K9 and K14 acetylation are typically considered marks of 
transcriptional activation, in the case of IFN responsive genes (described in detail below), 
H3K4 trimethylation and H3K9 and K14 acetylation are present at non-transcriptionally 
active genes and are, in fact, marks of preactivation (Escoubet-Lozach et al., 2011).  
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Further, H3K79 methylation is very contextual, having strong activation and repression 
effects based on the surrounding hPTMs (Frederiks et al., 2008).  As well, hPTMs are 
also involved in post-transcriptional effects including splicing (Enroth et al., 2012; Kim 
et al., 2011) and in DNA replication (Petruk et al., 2012).  As such, hPTMs add a layer of 
complexity and control to DNA transcription, translation, and replication. 
 
1.5 Innate immunity and histone post-translational modifications (hPTM).   
As mentioned above, in recent years, the impact of chromatin state and the necessity of 
hPTMs in modulating transcription has begun to unfold.  hPTMs act to modulate the 
activity of the underlying chromatin by providing complex information for the cells 
transcriptional machinery beyond the DNA sequence (Chi et al., 2010; Jenuwein and 
Allis, 2001). To further this complexity, it has been shown that hPTMs work in concert, 
rather than on their own (as described above). The overall composition of the hPTMs at a 
particular gene work together to specify the transcriptional state of the gene.  With 
regards to innate immunity, IFN target genes have interesting and complex hPTM 
patterns. During non-stimulated conditions the promoters of many IFN target genes 
display the appearance of being fully operational based on hPTM status (Escoubet-
Lozach et al., 2011). These genes are marked by hPTMs traditionally associated with 
active transcription in the form of H3K4me3. As well, RNA polymerase II is loaded on 
the transcriptional start site (Escoubet-Lozach et al., 2011).  Interestingly, only barely 
detectable levels of transcription occur under these conditions despite the presence of 
chromatin marks typically indicative of active transcription. Furthermore, transcripts 
show defects in elongation, displaying premature termination and high levels of 
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transcriptional pausing (Escoubet-Lozach et al., 2011).  Upon stimulation, hPTMs 
associated with elongation, such as histone 2B monoubiquitination (H2B-ub) or histone 4 
acetylation, are introduced to the chromatin (Escoubet-Lozach et al., 2011; Fonseca et al., 
2012).  Thus, the primed hPTM status may allows for faster exchange to a fully active 
transcriptional state. As a result, expression of IFN target gene products and activation of 
innate immunity is able to occur in mere hours after stimulation by IFN through the 
ISGF3 complex (Waddell et al., 2010; Taylor and Mossman, 2012; Fonseca et al., 2012). 
 
1.6 hBre1 and monoubiquitination of H2B.  
hBre1 is an E3 ubiquitin ligase which acts in conjunction with the highly similar RNF40 
protein, the Ube2b conjugase (E2), and an accessory factor of unknown function, WAC1, 
to monoubiquitinylate histone 2B (H2B) at lysine 120 in mammalian cells.  This is done 
in the presence of the hPaf1c transcriptional regulatory complex (Hwang et al., 2003; 
Xiao et al., 2005; Wood et al., 2003; Zhang and Yu, 2011; Kim and Roeder, 2009; 
Krogan et al., 2002).  hBre1 and the associated H2B-ub activity are not global hPTMs, 
but are only associated with small subsets of genes. H2B-ub has been found to be 
necessary for two important processes: transcriptional pre-initiation and efficient 
transcriptional elongation.  Firstly, during formation of the transcriptional pre-initiation 
complex, H2B-ub, mediated by the hBre1 complex, acts as a signal for subsequent 
monoubiquitinylation and thereby activation of an integral structural component of the 
COMPASS complex, Cps35 (Lee et al., 2007).  COMPASS, using the SET1 complex, 
then acts to trimethylate H3K4 (Wood et al., 2003; Lee et al., 2007).  As well, H2B-ub 
acts as a signal to the DOT1 complex through as yet unknown means to trimethylate 
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Figure 1.7. hBre1 facilitates transcriptional initiation.  PAF1 coordinates targeting of the 
Bre1 complex to target genes.  The hBre1/RNF40/Ube2b complex subsequently 
monoubiquinates H2B at K120 (mammals).  After this, the Cps37 component of the MLL 
complex, which is necessary for catalytic activity, is targeted by hBre1 for 
monoubiquitination.  The MLL complex may then associate with the SET1 
methyltransferase complex, which targets H3K4 for trimethylation. H2B 
monoubiquintylation also acts as a signal for the trimethylation of H3K79 by the DOT1 
complex.  These two methylation events are signals for transcriptional initiation by RNA 
Polymerase II. 
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H3K79 (Wood et al., 2003; Shahbazian et al., 2005; Mohan et al., 2010). Both of these 
chromatin modifications are markers for transcriptional activation.  The combination of 
H2B-ub, and H3K4 and K79 trimethylation along with hPaf1c recruitment by hBre1 
appear to cooperate to recruit the RNA polymerase II complex to initiate transcription 
(Figure 1.7) (Lee et al., 2007; Xiao et al., 2005).  Secondly, hBre1 is necessary for 
efficient transcriptional elongation (Minsky et al., 2008; Xiao et al., 2005).  In this 
process, the ubiquitin moiety of H2B-ub acts as a signal for the FACT complex (Pavri et 
al., 2006).  Prior to transcriptional elongation by RNA polymerase II, FACT removes 
H2A/H2B-ub dimers from the nucleosome, effectively converting the histone octamer to 
a hexamer (Pavri et al., 2006).  This effectively alters the compaction of DNA in the 
nucleosome, allowing RNA polymerase II to more efficiently transcribe the affected 
chromatin.  FACT then acts with the Ubp8 component of the SAGA complex, to remove 
the ubiquitin moiety from H2B and replaces H2B in the nucleosome following the 
passage of the transcriptional elongation complex (Figure 1.8) (Henry et al., 2003; Wyce 
et al., 2007).  The combination of these two activities has the effect of making the H2B-
ub moiety an hPTM associated with not just actively transcribed chromatin, but with 
rapid increases in transcriptional activation (Henry et al., 2003; Pavri et al., 2006; Wyce 
et al., 2007).  This is evidenced in the fact that hBre1 mediated H2B-ub is associated with 
the transcribed regions of highly expressed genes (Minsky et al., 2008).  To date, 
mammalian H2B-ub has been implicated in the transcriptional activation of small subsets 
of genes including HOX, Notch, estrogen receptor, DNA damage response, MLL 
rearrangement events and p53 responses (Moyal et al., 2011; Bray et al., 2005; Mohan et 
al., 2010; Nakamura et al., 2011; Prenzel et al., 2011; Shema et al., 2008; Zhu et al., 
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2005; Wang et al., 2013).  Interestingly, recent reports have suggested that O-linked N-
acetylglucosamine (GlcNAc) catalyzed by two enzymes, O-GlcNAc transferase and O-
GlcNAcase, onto serine 112 of H2B may facilitate H2B-ub at K120 by functioning as a 
docking site for hBre1 (Fujiki et al., 2011). 
1.7 Thesis Overview 
The work within this thesis identifies and characterizes an interaction between hBre1 and 
E1A.  Further, we show the mechanisms by which the viral E1A protein uses this cellular 
protein both for transcriptional repression of cellular transcription and activation of viral 
transcription. 
 
1.7.1 Chapter 2:  Adenovirus evasion of interferon mediated innate immunity by 
direct antagonism of a cellular histone post translational modification 
In this study, we found an increase of H2B-ub upon infection with a virus lacking E1A as 
a result of an IFN regulated innate immune response.  This increase correlated with an 
increase in ISG transcription.  We then showed the ability of E1A to block these 
increases.  This lead to the initial evidence for the interaction between E1A and hBre1, a 
member of the complex involved in H2B-ub, as well as defining the interaction to 
residues 4-25 on E1A.  hBre1 was shown to be necessary for full ISG transcription 
through H2B-ub.  The ability of E1A to block ISG transcription is a direct result of 
binding hBre1 and dissociating it from other members of the hBre1complex, which are 
necessary for monoubiquitinating H2B.  Lastly, growth of an HAdV lacking residues 4-
25 of E1A, which was previously shown to be susceptible to IFN treatment, was partially 
rescued by knockdown of hBre1 and associated complex members. 
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Figure 1.8.  hBre1 mediated transcript elongation. Upstream of the elongating RNA 
polymerase II transcription complex, monoubiquitination of H2B acts as a signal for the 
Facilitates chromatin transcription (FACT) complex to remove H2A/H2B-ub dimers 
from the nucleosome.  This disturbs the tightly packed nature of the coiled DNA 
surrounding the nucleosome and facilitates transcriptional elongation by RNA 
polymerase II, along with human Polymerase Accessory Factor 1 (hPaf1).  The ubiquitin 
moiety is then removed from H2B by the SAGA associated deubiquitinase Usp22.  
FACT then restores nucleosome integrity by reintroducing H2A/H2B dimers downstream 
of elongating transcript.  This process is  thought to be necessary for efficient 
transcription of highly transcribed genes. 
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1.7.2 Chapter 3:  Viral retasking of hBre1/RNF20 to recruit hPaf1 for transcriptional 
activation  
Following the previous chapter, we examined the effect of hBre1 on E1A mediated 
transcriptional activation of HAdV early genes.  We found that hBre1 is necessary for 
E1A mediated transcription in an artificial Gal4 fusion system.  We then found that 
hBre1 was localized to viral early genes in an E1A dependent manner and is necessary 
for full expression of several viral early genes.  This activation did not occur through 
H2B-ub, which is disrupted by E1A during HAdV infection.  Instead, hBre1 acted as a 
scaffold to recruit hPaf1 to HAdV early genes. 
These results illustrate both the intricacy and economy with which the E1A 
protein works to modulate the cellular environment through specific cellular interactions.  
As well, these studies show the continuing value of studying viral proteins to identify 
critical regulators of cellular processes and understand their mechanism of action. 
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Chapter 2: 
Adenovirus evasion of interferon mediated innate immunity by 
direct antagonism of a cellular histone post translational 
modification 
2.1 Introduction 
Eukaryotic DNA is compacted via association with protein to form a highly organized 
polymer called chromatin (Campos & Reinberg, 2009). The fundamental subunit of 
chromatin is the nucleosome, which is formed by wrapping DNA around an octamer of 
histone proteins.  hPTMs actively alter chromatin structure in a dynamic and often 
reversible process (Campos & Reinberg, 2009; Li et al., 2008; Rice et al., 2003).  These 
enzyme mediated covalent histone modifications affect the compaction of cellular 
chromatin and are vital for any process requiring access to the DNA template 
(Braunstein, Rose, & Holmes, 1993; Rice et al., 2003; Sullivan & Karpen, 2004).  In 
particular, many of these modifications directly or indirectly influence the recruitment of 
transcriptional regulatory factors to chromatin, providing an additional mechanism to 
control gene expression Garske et al., 2010; Li et al., 2008; Wysocka, 2006).  Mounting 
evidence suggests that global changes in histone modifications lead to global changes in 
gene expression during disease processes including cancer and infection (Chi, Allis, & 
Wang, 2010; Ferrari, Berk, & Kurdistani, 2009; Lilley et al., 2010). 
 Viruses are obligate intracellular pathogens.  As such, they have evolved simple, 
yet elegant mechanisms to reprogram cellular systems for the benefit of the virus.  Not 
66 
 
surprisingly, many viruses target and utilize hPTMs to modify cellular and viral 
transcription and optimize the cellular environment for virus replication.  Human 
adenovirus (HAdV) is a small DNA tumour virus that is able to transform cells and cause 
malignancies in rodents (Pelka, Ablack, Fonseca, Yousef, & Mymryk, 2008).  As an 
infectious human pathogen, HAdV only has access to the terminally differentiated cells 
of the exposed epithelial surfaces in the respiratory and gastrointestinal tracts. These 
quiescent cells do not provide an ideal environment for virus replication. To overcome 
this difficulty, the E1A proteins of HAdV have evolved to reprogram this suboptimal 
cellular environment into one more conducive to virus replication.  E1A is the first viral 
gene expressed during infection and it plays critical roles in modulating transcription, 
forcing infected quiescent cells back into the cell cycle and suppressing cellular innate 
anti-viral responses.  The interaction between the viral E1A protein and several enzymes 
comprising the cellular hPTM apparatus, particularly the p300/CBP acetyltransferases, is 
well established and E1A exploits these interactions to alter gene expression and cell 
growth (Pelka et al., 2008).  Indeed, recent work has established that E1A globally 
reprograms histone 3 lysine 18 (H3-K18) acetylation in order to coerce quiescent cells to 
replicate in a process akin to that observed in some cancers (Horwitz et al., 2008).   
hBre1/RNF20 is a member of a complex involved in the monoubiquitination of H2B at 
lysine 120 (H2B-ub) and we detected it as an interacting partner of E1A in a yeast two-
hybrid screen.  In this study, we have focused on characterizing the effect of E1A on 
global H2B-ub.  In eukaryotes, H2B-ub marks chromatin that is highly transcriptionally 
active and is involved in efficient transcript elongation (Lee et al., 2007; Xiao et al., 
2005).  H2B-ub is a precursor to several other epigenetic marks of transcriptional 
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Figure 2.1.  Virus infection and IFN treatment induces a global increase in H2B-ub.  (A)  
Western blot analysis of H2B and H2B-ub, E1A and actin proteins extracted from HAdV 
infected A549 cells over a 48 hour time course. (B)  UV inactivated HAdV and myxoma 
viruses and IFN treatment stimulate a global increase in H2B-ub.  A549 cells were 
infected with the indicated viruses or treated with IFNβ1.  Cell extracts were analyzed as 
in (A) and also blotted for GFP to demonstrate successful Myxoma infection. (C) E1A 
expression is sufficient to block an IFN induced global increase in H2B-ub.  Parental 
A549 and A549 cells stably expressing E1A were treated with IFNβ1 over 48 hours.  
Cells extracts were analyzed as in (A).   
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activation including tri-methylation of histone 3 at lysines 4 (H3-K4) and 79 (H3-K79) 
by the COMPASS and DOT1 complexes (Lee et al., 2007).H2B-ub is also required for 
the displacement of H2B from the nucleosome by the FACT complex (Xiao et al., 2005).  
This is thought to loosen the surrounding DNA and allow for efficient passage of the 
RNA polymerase II complex during transcript elongation.  These effects on transcription 
make regulation of the H2B-ub hPTM a candidate target for a strong viral transcriptional 
regulator such as E1A.   
 
2.2 Results 
2.2.1 Cellular levels of H2B-ub greatly increase in response to viral infection.   
To assess the effects of HAdV infection on global H2B-ub levels, we infected human 
A549 lung adenocarcinoma cells with either wild type HAdV type 5 (WT) expressing the 
full length E1A protein or a virus lacking E1A (ΔE1A) and collected cells over the 
following 48 hours (Figure 2.1A).  HAdV ΔE1A is severely impaired in the ability to 
reprogram the gene expression profile of the infected cell (Ferrari et al., 2008) and would 
not be expected to actively affect global histone modifications.  Unexpectedly, infection 
with HAdV ΔE1A stimulated a strong global increase in H2B-ub by 8 hrs post infection 
that was sustained over the course of our analysis.  This suggests that cells responded to 
the presence of ΔE1A virus by globally increasing H2B-ub levels.  However, this 
increase was largely abrogated during infection with the wild type virus, which expresses 
E1A (Figure 2.1A).  This was also observed during infection of murine embryonic 
fibroblasts and the human diploid lung fibroblast line WI-38 (Figures 2.2A, 2D).  These 
results suggested that HAdV utilizes E1A to actively block the cellular upregulation of  
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Figure 2.2. Investigation of IFN signalling during HAdV infection.  Data significantly 
different than control within groups is indicated (*P<0.05).  (A) H2B-ub is not 
upregulated in response to infection in cells that are not IFN responsive. Western blot 
analysis of H2B and H2B-ub in WI-38 and Vero cells treated with IFN or infected with 
HAdV. (B) IRF3 is activated in response to WT HAdV infection.  A549 cells were 
infected with WT HAdV and samples were collected over the course of 36 hours.  
Western blots were then performed on protein extracts with antibodies for IRF3, active 
IRF3 phosphorylated on S396 (IRF3(S396)) or Actin.  (C) IRF3 associates with the 
IFNβ1 promoter during WT HAdV infection.  A549 cells were infected with WT HAdV 
or HAdV ∆E1A or treated with IFNβ1 for 8 hours.  Chromatin immunoprecipitation 
(ChIP) was then performed.  Chromatin was analyzed for the presence of IRF3. DNA 
was quantitated via qReal Time PCR using primers specific to the IFNβ1 promoter. (D) 
Induction of a global increase in H2B-ub by viral infection requires IRF3 and the type I 
IFN receptors.  WT mouse embryonic fibroblasts (MEFs) or MEFs lacking IRF3(IRF3-/-) 
or the IFNα and IFNβ receptors (INFRαβ-/-) were infected at an MOI of 20 plaque 
forming units/cell with either WT HAdV or HAdV E1A ∆4-25 or treated with IFNβ1 for 
16 hours. Western blots were then performed on acid extracted chromatin to detect global 
levels of H2B-ub and total H2B.  (E) Repression of NF-κβ activity requires a region of 
E1A not involved in blocking H2B-ub.  U2OS cells were transfected with an NF-κβ 
responsive luciferase reporter and a constitutive β-galactosidase reporter.  After 2 days, 
cells were infected with the indicated HAdV for 16 hours.  Activity of the NF-κβ reporter 
was assayed via luciferase activity.  Data was normalized to the constitutive β-
galactosidase reporter activity determined via the ONPG colorimetric assay.  A Western 
blot for the expression levels of the various E1A mutants is shown in the inset.  (F) E1A 
dependent activation of HAdV E4 orf3 expression requires a region of E1A not involved 
in blocking H2B-ub.  A549 cells were infected at an MOI of 5 plaque forming units/cell 
with virus expressing the indicated E1A mutants for 16 hours.  Cell lysates were 
collected for protein analysis and RNA was extracted.  E4 orf3 mRNA levels were 
determined by quantitative RT-PCR and normalized to E1A expression level.  A Western 
blot for the expression levels of the various E1A mutants is shown in the inset.  Error bars 
represent +/- SD.  
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the H2B-ub modification that occurs in response to virus infection.  Global H2B-ub was 
also stimulated upon infection by UV inactivated wild type HAdV (WT UVK) or the 
rabbit specific poxvirus, Myxoma virus (Myxoma UVK) (Figure 2.1B).  H2B-ub was 
reduced or blocked completely when cells were treated with native viruses (Figure 2.1B). 
Interestingly, despite representing different virus families, both HAdV and Myxoma 
appear to have evolved strategies that antagonize this cellular anti-viral response to virus 
exposure. Thus, the observed global H2B-ub increase in response to virus infection likely 
results from a cellular innate immune response to virus particles, rather than from the 
activity of a viral protein. 
 
2.2.2 Cellular levels of H2B-ub are greatly increased by type I IFN treatment.   
Production of type I interferon (IFN) from virus-infected cells is the hallmark 
characteristic of innate antiviral immunity. Type I IFN exposure alters the expression of 
numerous cellular interferon-stimulated genes (ISGs) (Der, Zho, Williams, & R.H., 1998; 
Takaoka & Yanai, 2006), rendering the cell more resistant to viral infection (Sadler & 
Williams, 2008).  We reasoned that the robust activation of over 300 cellular genes by 
type I IFN could be responsible for the observed global upregulation of H2B-ub levels in 
response to virus. When tested directly, treatment of A549 cells with the interferon β1 
(IFNβ1) cytokine stimulated a strong global increase in H2B-ub levels similar to that 
induced by infection with defective viruses (Figure 2.1B).  In addition, neither treatment 
with IFN nor infection with HAdV ΔE1A increased H2B-ub levels in Vero cells, which 
are unable to produce IFNβ1 in response to viral infection (Figure 2.2A).  These data 
connect type I IFN induced antiviral immunity with a localized change in the H2B-ub 
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Figure 2.3.  Infection upregulates global H2B-ub and ISG transcription in an hBre1 
dependent manner and this is blocked by HAdV E1A via residues 4-25.  (A)  A549 cells 
were infected with HAdV expressing wild type E1A (WT) or the indicated E1A deletion 
mutants in the presence or absence of IFNβ1.  Western blot analysis was performed as in 
Figure 2.1A.  (B)   A549 cells were infected with a panel of HAdV viruses alone or 
cotreated with IFNβ1 for 16 hrs and RNA was extracted.  Data was normalized to 
GAPDH and set to fold increase over the uninfected control.  A statistically significant 
decrease in the transcription of all tested ISGs was found in WT HAdV infected as well 
as HAdV E1A Δ26-35 and HAdV E1A Δ30-49 infected cells as compared to HAdV 
ΔE1A and HAdV Δ4-25 infected cells (P<0.001).  No significant difference was detected 
virus alone or treated with IFNβ1.  (C)  A549 cells were treated with control siRNA or 
siRNA specific for hBre1 and infected with WT HAdV, HAdV ∆E1A, or IFNβ1 and 
RNA was extracted.  RT-qPCR was performed with a panel of ISGs, normalized to 
GAPDH and fold change to uninfected ctrl siRNA treated cells was plotted.  Control 
siRNA treated HAdV ΔE1A and IFNβ1 treated cells were found to be statistically 
significant from all other groups while all hBre1 siRNA treated groups were not found to 
be statistically upregulated as compared to uninfected control treated cells (P<0.001).  
Error bars represent +/- SD.  
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histone modification. 
 
2.2.3 E1A residues 4-25 are necessary to block H2B-ub and ISG upregulation by type 
I IFN.   
Transcription of ISGs has long been known to be induced by HAdV particles and E1A is 
known to block this type I IFN mediated response, although the exact mechanisms have 
not been elucidated (Anderson & Fennie, 1987; Kalvakolanu, Bandyopadhyay, Harter, & 
Sen, 1991; Reich, Pine, Levy, & Darnell, 1988).  We confirmed that E1A alone is 
necessary and sufficient to block the IFNβ1 induced global increase in H2B-ub in A549 
cells by producing an A549 line that stably expresses E1A (Figure 2.1C). 
 To map the region of E1A required for blocking the type I IFN induced global 
increase in H2B-ub levels, we infected cells with a panel of viruses containing deletions 
within the E1A protein in the presence or absence of IFNβ1 (Figures 2.3A, 4A).  A virus 
lacking residues 4-25 of E1A behaved similarly to the ΔE1A virus and triggered a global 
increase in H2B-ub.  Deletions in adjacent regions (Δ26-35 and Δ30-49) functioned in a 
manner similar to WT E1A expressing virus, as infection with these viruses did not 
induce H2B-ub.  Thus, the N-terminal region of E1A is essential for inhibition of H2B-ub 
induction.  Identical results were seen in the presence or absence of IFNβ1, 
demonstrating that E1A effectively abrogates the induction of H2B-ub whether it is 
indirectly induced by cellular recognition of the virus particle or directly by exposure to 
IFNβ1.  We also compared the transcriptional effects of virus infection and type I IFN 
treatment on a representative subset of well established ISGs (Figure 2.3B) and a panel of 
control genes not known to be IFN responsive (Figures 2.5B-E).  As expected, IFNβ1 
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Figure 2.4. Mutants of E1A and their properties. (A) Schematic depiction of HAdV5 E1A 
and the mutants used in this study.  (B) Relevant protein interaction properties of the E1A 
mutants (p300/CBP, pRB (Mymryk et al., 1992), and pCAF (Pelka et al. 2009)) used in 
this study and their experimentally determined phenotypes. 
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treatment strongly induced expression of all six ISGs, but not the control genes.  The 
effect of virus infection on ISG expression, but not the control genes, closely mirrored the 
effects seen on global H2B-ub levels during virus treatment.  Specifically, infection with 
HAdV ΔE1A or the Δ4-25 virus caused a robust increase in ISG transcriptional activation  
similarly to IFNβ1 treatment.  However, WT HAdV as well as viruses with deletions in 
E1A adjacent to 4-25 largely blocked activation of ISG expression.  This data establishes 
a strong correlation between the ability of E1A to block IFN dependent transcription with 
the ability to block global increases in H2B-ub levels. 
 
2.2.4 The early stages of the type I IFN response are not blocked by E1A.   
During infection with WT HAdV, IRF3 became phosphorylated and was recruited to the 
IFNβ1 promoter (Figures 2.2B, C).  Thus, the earliest stages of the type I IFN response 
induced by infection remain intact.  However, the global increase in H2B-ub induced by 
E1A mutant HAdV were not detected in MEFs deficient for both the type I IFN receptors 
(IFNα/βR-/-) or  MEFs lacking IRF3 (IRF3-/-) (Figure 2.2D).  This confirmed that the 
increase in H2B-ub levels, observed upon infection with HAdV expressing mutant E1A 
was dependent on the IFN response.  Given that NF-κβ is a key regulator of 
inflammation, we determined if the region of E1A necessary to repress NF-κβ activity is 
the same as that required to repress ISG transcription.  We compared the ability of the 
panel of E1A mutant viruses to affect the NF-κβ response.  While WT E1A could repress 
NF-κβ activation, all of the N-terminal E1A mutants have lost this ability (Figure 2.2E).  
As several E1A mutants are unable to repress NF-κβ dependent transcription but are still 
able to block type I IFN responses, this activity may be of secondary importance for viral 
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evasion of the innate immune response.  As the viral E4 region encodes E4 orf3 which is 
known to antagonize the IFN-induced antiviral state (Ullman, Reich, & Hearing, 2007), 
we examined whether the effects of E1A could also be mediated via activation of viral E4 
expression.  As reported (Nevins, 1981), E1A does activate E4 expression.  However, an 
E1A mutant (Δ30-49) unable to activate E4 orf3 expression was still able to block type I 
IFN responses (Figures 2.2F, 3B). This indicates that E4 mediated effects are not 
necessary for the inhibition of ISG expression, and this agrees with our observation that 
E1A expression alone was necessary and sufficient to block IFNβ1 effects (Figure 2.1C). 
 
2.2.5 hBre1 is necessary for IFN induced gene transcription.   
Human Bre1/RNF20 (hBre1) is the E3 ubiquitin ligase which acts in conjunction with the 
E2 ubiquitin conjugase Ube2b, and accessory factors RNF40 and WAC to 
monoubiquitinate H2B at lysine 120 (Hwang et al., 2003; Kim et al., 2009; F. Zhang & 
Yu, 2011).  While H2B-ub is a hPTM that is generally associated with transcriptional 
activation, hBre1 depletion only affects the expression of a small subset of genes (Shema 
et al., 2008).  However, the involvement of hBre1 in IFN-induced activation of ISG 
transcription has never been assessed.  A549 cells were treated with either a nonspecific 
control siRNA or an siRNA specific for hBre1, and then exposed to WT HAdV, HAdV 
ΔE1A or IFNβ1.  The expression level of six ISGs (Figures 2.3C) and a panel of control 
genes not responsive to IFNβ1 (Figures 2.5B-E) were determined.  As expected, IFNβ1 
and HAdV ΔE1A induced high levels of ISG transcriptional activation in cells treated 
with a nonspecific control siRNA, whereas wild type HAdV did not strongly stimulate 
ISGs (Figure 2.3C).  In contrast, knockdown of hBre1 with specific siRNA blocked ISG 
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Figure 2.5. The hBre1 complex regulates expression of specific cellular genes.  (A) 
RNF40 is required for ISG transcriptional activation.  A549 cells were treated with 
siRNA specific for RNF40 or a non-specific control siRNA and infected with WT virus, 
∆E1A virus, or treated with IFNβ1.  cDNA was made from the extracted RNA and 
quantitative real-time PCR (RT-qPCR) was performed, normalized to GAPDH and fold 
change to uninfected cells was plotted. Control siRNA treated HAdVΔE1A and IFNβ1 
treated cells were found to be statistically significant from all other groups, while all 
RNF40 siRNA treated groups were not found to be statistically upregulated as compared 
to uninfected control treated cells (P<0.001).  (B) Knockdown of hBre1 or RNF40 does 
not reduce the expression of non-ISGs.  RT-qPCR was similarly performed with a panel 
of non-ISGs which are not regulated by IFN or E1A.  (C-D) Knockdown of hBre1 or 
RNF40 does not alter the ability of E1A to activate or repress the expression of non-ISGs. 
RT-qPCR was similarly performed with a panel of non-ISGs which are increased during 
HAdV infection (C) or decreased during HAdV infection (D).  Interestingly, while none 
of these genes are reported ISGs, Mcm3 and fhl2 responded weakly to IFNβ1 and this 
was reduced by knockdown of hBre1 or RNF40.  (E-F) E1A does not block the 
expression of hBre1 regulated genes that are not ISGs.  RT-qPCR was similarly 
performed with a panel of non-ISGs which are regulated by hBre1.  Results obtained 
from uninfected cells shown in panel (E) were normalized with respect to Ctrl siRNA 
values to visualize their dependence on hBre1 and RNF40 (F).  Data significantly 
different than uninfected control within groups is indicated (*P<0.05).  Error bars 
represent +/- SD.   
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transcriptional activation under any treatment condition (Figure 2.3C).  Similar results 
were obtained with siRNA against RNF40 (Figure 2.5A).  This data provides evidence 
that the hBre1 complex is an essential component of the IFN stimulated antiviral 
response and links transcriptional activation of ISGs and the ensuing innate immune 
response with hPTM changes in H2B-ub status.  These effects appear specific, as 
expression of the non-IFN responsive genes were not decreased by knockdown of hBre1 
or RNF40 (Figure 2.5B).  Furthermore, knockdown of either hBre1 or RNF40 had no 
effect on a panel of non-ISGs known to be affected by E1A (Figure 2.5C, D) and little if 
any H2B-ub could be detected on these genes by Chromatin Immunoprecipitation (ChIP) 
assays (Figure 2.6).  We also examined the effect of E1A on three genes reported to be 
regulated by hBre1 (HoxA10, fosL2 and p53).  Although expression of each of these 
genes was reduced upon knockdown of hBre1 or RNF40 (Figure 2.5F) and had detectable 
levels of H2B-ub (Figure 2.6), their expression was not blocked by E1A (Figure 2.5E).  
Thus, the effects of E1A on hBre1 may not affect genes with H2B-ub that exists prior to 
infection or they may be restricted in some other fashion to ISGs.  This may be related to 
the observation that recruitment of E1A to cellular promoters varies temporally, such that 
several distinct classes of promoters have been defined based on the kinetics of E1A 
occupancy (Ferrari et al., 2008). 
 
2.2.6 The hBre1 complex is disrupted by E1A.   
E1A is an intrinsically disordered protein that functions by binding to cellular proteins 
and affecting their normal functions (Ferreon, Martinez-Yamout, Dyson, & Wright, 2009; 
Pelka et al., 2008).  We, therefore, tested the ability of E1A to physically interact with 
83 
 
 
Figure 2.6.  E1A does not affect the H2B-ub status of non-ISGs.  (A) The H2B-ub status 
of non-ISGs activated by E1A is not altered by infection.  A549 cells were infected with 
HAdV ∆E1A or WT HAdV or treated with IFNβ1 for 16 hours.  Chromatin 
immunoprecipitation (ChIP) was then performed using a nonspecific control antibody or 
antibodies specific for H2B, H2B-ub, hBre1, Ube2b or E1A. DNA was then quantitated 
via RT-qPCR using gene specific primers located within the transcribed region of each 
indicated gene.  (B) The H2B-ub status of non-ISGs repressed by E1A is not altered by 
infection. Experiment was performed as in (A). (C) E1A does not affect H2B-ub levels at 
genes that are regulated by hBre1, but not IFN. Experiment was performed as in (A).  
Data significantly different than uninfected control within groups is indicated (*P<0.05).  
Error bars represent +/- SD.   
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members of the hBre1 complex, which includes hBre1, RNF40 and Ube2b.  To do this, 
we infected A549 cells with HAdVs expressing either WT or deletion mutant E1A 
proteins.  Lysates from infected cells were immunoprecipitated using an E1A specific 
antibody and the presence of hBRE1, RNF40 and Ube2b was assayed by immunoblotting 
using antibodies specific to these proteins (Figure 2.7A).  Both hBre1 and RNF40, but 
not Ube2b co-precipitated with E1A.  Furthermore, the association of E1A with hBre1 
and RNF40 required E1A residues 4-25 (Figure 2.7A), the same residues which are 
required to block global increases in H2B-ub levels and IFN induced ISG transcription 
(Figures 2.3A, B).  The interaction between E1A and hBre1 was further confirmed by co-
immunoprecipitation of E1A with endogenous hBre1 (Figure 2.8A) or transfected epitope 
tagged hBre1 or RNF40 (Figure 2.8B). However, E1A did not co-immunoprecipitate with 
epitope tagged Ube2b (Figure 2.8B). 
The inability of E1A to interact with Ube2b suggested that E1A interfered with 
the association between hBre1 and the Ube2b catalytic subunit.  Perturbation of the 
interaction between the hBre1/RNF40 E3 ligase with the E2 conjugase Ube2b provides 
an attractive mechanism by which E1A could block type I IFN induced H2B-ub and 
antiviral gene expression. To test this directly, we transfected tagged hBre1 and Ube2b 
along with wild type E1A or E1A mutants into HT1080 cells.  As expected, hBre1 was 
readily co-immunoprecipitated with Ube2b (Kim et al., 2009) in the absence of E1A 
(Figure 2.7B).  However, this interaction was disrupted in the presence of E1A, and this, 
once again, required residues 4-25 of E1A (Figure 2.7B).  Thus, the identical region of 
E1A (residues 4-25) that is required to abrogate type I IFN induction of H2B-ub levels 
and ISG expression (Figures 2.3A, B) was also required for the association with and 
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Figure 2.7.  E1A binds hBre1 through residues 4-25 and this blocks hBre1 association 
with Ube2b.  (A)  A549 cells were infected with wild type HAdV or HAdV expressing 
the indicated E1A deletion mutants for 16 hours at an MOI of 5.   E1A was 
immunoprecipitated and Western blots were performed using antibodies specific to the 
indicated hBre1 complex components.  (B)  HT1080 cells were transfected with E1A or 
an E1A deletion mutant as well as tagged hBre1 and tagged Ube2b.  Co-
immunoprecipitation was performed by IP with an antibody specific to tagged Ube2b.  
Western Blot analysis was performed with an antibody specific to the tagged hBre1.
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disruption of the hBre1 complex (Figure 2.7B).  Serial immunoprecipitation of 
endogenous E1A from HEK 293 cells showed that a substantial amount of hBre1 was not 
co-immunoprecipated with E1A.  This suggested that E1A interacted with only a small, 
and perhaps distinct, subset of the total cellular hBre1 pool (Figure 2.8C).  This data 
supports a model whereby the interaction of E1A with the hBre1 complex specifically 
blocks H2B-ub, which is required for gene expression, by excluding the catalytic Ube2b 
ubiquitin conjugase subunit from the hBre1 complex. 
 
2.2.7 hBre1 and Ube2b are recruited to ISGs during innate immune stimulation.   
H2B-ub is considered to be a hPTM that is preferentially associated with chromatin that 
is transcribed at high levels (Batta, Zhang, Yen, Goffman, & Pugh, 2011; Shema et al., 
2008).  Given the requirement of hBre1 for type I IFN induced gene expression, we 
predicted that H2B-ub would be present in the transcribed chromatin of actively 
expressed ISGs.  Indeed, chromatin immunoprecipitation assays (ChIPs) determined that 
H2B-ub was present within the transcribed regions, as well as the promoter regions, of a 
panel of ISGs upon infection with HAdV ΔE1A or treatment with IFNβ1 (Figures 2.9, 
10).  Furthermore, this chromatin modification was not present during wild type HAdV 
infection (Figures 2.9, 2.10) suggesting that expression of E1A was locally inhibiting this 
histone modification as a mechanism to block type I IFN induced antiviral gene 
expression.  Unlike wild type virus, infection with HAdV E1A Δ4-25 induced H2B-ub in 
the transcribed regions of ISGs (Figure 2.9) further indicating that this region was 
essential for antagonizing IFN induced H2B-ub.  ChIP analysis also demonstrated 
strongly increased Bre1 occupancy of the ISGs in response to infection with WT HAdV, 
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Figure 2.8.  Interaction of E1A with the hBre1 complex.  (A) E1A is co-
immunoprecipitated with endogenous hBre1.  A549 cells were infected with a panel of 
HAdV at an MOI of 5 plaque forming units/cell.  Cells were lysed and 5mg of protein 
was used to perform co-immunoprecipitation.  Lysate was immunoprecipitated with 3µg 
of α-hBre1 specific antibody.  Membranes were then blotted with E1A specific antibodies 
(M73).  (B)  hBre1 and RNF40, but not Ube2b, interact with E1A and this requires 
residues 4-25 of E1A.  HT1080 cells were transfected with wild type E1A or the 
indicated E1A N-terminal deletion mutants and epitope tagged hBre1(left), RNF40 
(middle), or Ube2b (right).  After 24 hours, E1A was immunoprecipitated and Western 
blots were performed using antibodies specific to the indicated epitope tagged hBre1 
complex components.   (C) E1A targets a fraction of the cellular pool of endogenous 
hBre1.  HEK 293 cells, which endogenously express E1A, were lysed with NP40 lysis 
buffer and 5 mg of lysate was serially immunoprecipitated 3 consecutive times with an α-
E1A specific antibody.  Input corresponds to 2% of the total lysate at the start of each 
round.  Membranes were then blotted with antibodies specific for hBre1 and E1A.  
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HAdV ΔE1A or treatment with IFNβ1.  This occurred regardless of the presence or 
absence of E1A (Figure 2.11A).  This suggested that E1A does not interfere with 
recruitment of hBre1 to the target chromatin.  Indeed, hBre1 and E1A were found to co-
localize to ISGs during innate immune stimulation by ChiP reChIP experiments (Figure 
2.11B).  Furthermore, E1A was localized to the transcribed regions of ISGs during WT 
HAdV infection and could potentially be recruited via its interaction with hBre1.  Ube2b 
was found to localize with hBre1 within the transcribed region of ISGs after IFN 
treatment or exposure to HAdV ΔE1A (Figures 2.11A, 11C).  In contrast to hBre1, the 
Ube2b ubiquitin conjugase was absent in the presence of wild type E1A (Figure 2.11A). 
H2B-ub or hBre1 were not found within the transcribed regions of genes regulated by 
E1A, but not IFN (Figure 2.6).  Taken together, these data support a model whereby IFN 
treatment stimulates the localized formation of an enzymatically competent hBre1 
complex and subsequent H2B-ub modification of the chromatin of IFN regulated genes.  
E1A antagonized this process by displacing Ube2b from the hBre1 complex. 
Furthermore, H3-K4 and H3-K79 trimethylation in the promoter regions of ISGs was 
blocked under conditions in which H2B-ub was antagonized by E1A (Figure 2.10).  This 
was expected as these hPTMs are marks of transcriptional activation that require H2B-ub 
(Kim et al., 2009; Mohan et al., 2010).  This was not the case with H3 acetylation (H3ac) 
status, which has not been shown to depend on H2B-ub (Figure 2.10).  Specifically, 
changes in H3K18 acetylation of ISG promoters, which is another mark altered by E1A 
during infection, did not consistently correlate with transcriptional activation of ISGs or 
H2B-ub status (Figure 2.11D). 
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Figure 2.9.  The H2B-ub hPTM is present at ISGs upon IFN induction and this is blocked 
by  E1A.  The identity of each gene tested is indicated at the top of each figure.  A549 
cells were infected with WT HAdV, ∆E1A HAdV, E1A ∆4-25 HAdV or treated with 
IFNβ1 for 16 hours.  Chromatin immunoprecipitation (ChIP) was then performed.  
Chromatin was analyzed for the presence of the following proteins with specific 
antibodies: nonspecific control, H2B, and H2B-ub. DNA was then quantitated via qReal 
Time PCR using the indicated gene specific primers. Data significantly different than 
uninfected control within groups is indicated (*P<0.001).  Error bars represent +/- SD.  
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2.2.8 hBre1 is required for activation of the type I IFN mediated innate immune 
response against virus infection.  
To establish the biological significance of the interaction of E1A with the hBre1 
complex, we assessed the effect of type I IFN on virus replication.  A549 cells were 
treated with siRNA specific to hBre1, RNF40, or both hBre1 and RNF40 prior to 
infection in the presence or absence of IFNβ1.  Production of infectious viral progeny 
was assayed at various time points over 48 hours (Figures 2.12, 13).  WT virus was 
unaffected by IFNβ1 treatment or knockdown of hBre1 or RNF40 alone or in 
combination.  In stark contrast, growth of virus expressing E1A ∆4-25 was completely 
abrogated by IFNβ1 treatment (Figures 2.12, 13).  Importantly, knockdown of hBre1 or 
RNF40 alone or in combination by siRNA relieved the hypersensitivity of the E1A ∆4-25 
virus to IFN, allowing substantial virus replication in the presence of IFNβ1 (Figures 
2.12, 13).  Thus, the inability of this mutant to interact with the hBre1 complex greatly 
sensitized this virus to the IFNβ mediated innate immune response.  These data confirm 
the importance of the hBre1 complex in establishing the IFN mediated anti-viral state.   
 
2.3 Discussion 
This study has identified a previously unsuspected requirement for the hBre1 complex 
and its ability to enzymatically modify chromatin in the type I IFN response (Figure 
2.14).  hBre1 functions as a ubiquitin ligase in conjunction with ubiquitin conjugase 
Ube2b, and accessory factors RNF40 and WAC to monoubiquitinate H2B at lysine 120 
(Hwang et al., 2003; Kim et al., 2009; F. Zhang & Yu, 2011).  H2B-ub marks chromatin 
that is highly transcriptionally active, is involved in efficient transcript elongation 
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Figure 2.10. hPTMs related to H2B-ub are similarly induced by IFN and reduced by 
E1A.  Cells treated as above were ChIP’ed with a nonspecific control antibody or 
antibodies recognizing H2B, or the indicated hPTMs.  RT-qPCR was performed using 
primers specific to the promoter region.  Data significantly different than uninfected 
control within groups is indicated (*P<0.001).  Error bars represent +/- SD.  
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(Lee et al., 2007; Xiao et al., 2005) and is a precursor to several other epigenetic marks 
of transcriptional activation including tri-methylation of histone 3 at lysines 4 (H3-K4) 
and 79 (H3-K79) (Lee et al., 2007). 
 hBre1 depletion only affects the expression of a small subset of genes (Shema et 
al., 2008), suggesting that its serves a regulatory role that may be restricted for specific 
purposes.  Studies in yeast similarly support the concept that the H2B-ub hPTM is not 
necessary for the general control of transcription, as yeast unable to monoubiquinate 
H2B do not have obvious global defects (Hwang et al., 2003).  We directly confirmed 
that the hBre1 complex was required for the cellular IFN response by knocking down 
the hBre1 ubiquitin ligase or the accessory factor RNF40 (Figures 2.3C, 5A).  Specific 
knockdown of either factor using siRNA greatly reduced ISG expression that is directly 
induced in response to treatment with IFNβ1 or indirectly induced by infection with 
attenuated virus.  In contrast, targeted knockdown did not alter the expression of a panel 
of genes not known to be regulated by IFN (Figures 2.5B, C, D).  Furthermore, we 
detected each of the hBre1, RNF40 and Ube2b components of the hBre1 complex co-
occupying the coding regions of ISGs in response to activation of IFN signalling 
(Figures 2.11A, C).  These results directly demonstrate that the hBre1 complex is 
necessary for the IFN induced program of gene expression and further confirm that the 
activity of hBre1 is confined to specific transcriptional programs.  Our discovery that 
hBre1 is required for the transcriptional program induced by type I IFN adds 
substantially to the short list of pathways for which H2B-ub is an epigenetic 
modification required for expression.  To date, this has included HOX, Notch, estrogen  
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Figure 2.11.  Status of various hPTMs at ISG loci. (A) The hBre1 complex is recruited to 
IFNβ1 activated genes and E1A blocks the recruitment of Ube2b to chromatin.  A549 
cells were infected with WT HAdV, HAdV ∆E1A, or HAdV E1A ∆4-25 or treated with 
IFNβ1 for 16 hours.  Chromatin immunoprecipitation (ChIP) was then performed for the 
indicated genes.  Chromatin was analyzed for the presence of the following proteins with 
specific antibodies: nonspecific control, hBre1, Ube2b or E1A. DNA was then 
quantitated via RT-qPCR using the indicated gene specific primer. Data significantly 
different from uninfected control within groups is indicated (*P<0.01).  (B) ChIP reChIP 
was performed on WT HAdV infected cells.  Chromatin was initially precipitated with an 
anti-E1A antibody and then precipitated with either an hBre1 or mouse IgG control 
antibody.  Interaction was then determined on ISGs with a panel of primers specific to 
ISG transcribed regions.  Data is presented as an increase in enrichment of ChIP E1A, 
reChIP hBre1 over ChIP E1A reChIP mouse specific IgG control.  (*P<0.001). (C)  ChIP 
was performed on IFNβ1 treated cells using an antibody recognizing Ube2b.  Samples 
were reChIP’ed with antibodies specific for hBre1 or RNF40 to determine co-occupancy 
within the transcribed regions of a panel of ISGs during IFN stimulation.  Data is 
presented as an enrichment of ChIP Ube2b, reChIP hBre1 or RNF40 over ChIP Ube2b 
reChIP mouse specific IgG control.  (*P<0.01).  (D) H3K18 acetylation at ISGs does not 
correlate with gene activation or H2B-ub.  H3K18 acetylation status of ISG was 
determined via ChIP and RT-qPCR.  Data significantly different than uninfected control 
within groups is indicated (*P<0.05).  Error bars represent +/- SD.   
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receptor and p53 responses (Bray et al., 2005; Mohan et al., 2010; Moyal et al., 2011; 
Nakamura et al., 2011; Prenzel et al., 2011; Shema et al., 2008; Zhu et al., 2005).  Like  
the type I IFN response, in each of these cases, rapid and substantial increases in the 
transcription of target genes occur. 
 Interestingly, a global increase in H2B-ub was not observed during infection 
with live HAdV expressing E1A or when cells stably expressing E1A were exposed to 
IFNβ1.  Thus, the viral E1A protein is necessary and sufficient to overcome this IFNβ1 
dependent global upregulation of the H2B-ub hPTM.  Inhibition of the global increase 
in H2B-ub stimulated either by adenovirus infection or IFNβ1 treatment specifically 
required HAdV E1A residues 4-25 (Figure 2.3A).  E1A residues 4-25 were also 
required to block transcriptional activation of ISGs (Figure 2.3B).  However, adjacent 
regions of E1A necessary for binding other chromatin modifiers were not required to 
inhibit H2B-ub upregulation and ISG transcription (summarized in Figure 2.4B).  This 
excludes indirect effects of E1A mediated by its interaction with general and ubiquitous 
co-regulators of transcription.  We reasoned that E1A may instead function via direct 
interference with the cellular apparatus responsible for creating the H2B-ub hPTM.    
 We identified a physical interaction between E1A and the hBre1 complex, which 
required the exact same region of E1A necessary for blocking H2B-ub upregulation and 
ISG transcription (Figure 2.7A).  In addition, the interaction of E1A with hBre1 blocked 
its association with Ube2b, the catalytic component of the complex involved in 
monoubiquitination of H2B (Figure 2.7B) and prevented the association of Ube2b with 
ISG coding regions in response to IFN signalling (Figure 2.11A).  This provides an 
elegant mechanism by which E1A inhibits H2B-ub and subsequent epigenetic marks  
101 
 
 
Figure 2.12. Growth of a mutant adenovirus unable to bind the hBre1 complex is 
abrogated by type I IFN treatment and hBre1 or RNF40 knockdown complement this 
replication defect.  A549 cells were treated with control siRNA or siRNA specific to 
hBre1, RNF40 or both in combination prior to infection with WT virus (MOI of 10) or 
HAdV E1A ∆4-25 (MOI of 20). Infected cells were treated with or without IFNβ1.  Cells 
were collected at various time points up to 48 hrs post infection to prepare virus lysates.  
Production of infectious progeny virus was quantitatively assayed by plaque formation of 
on HEK 293 cells.  Data is shown over 24-48 hrs .  Growth of WT HAdV is unaffected 
by IFNβ1 treatment, whereas growth of HAdV E1A ∆4-25, which is unable to target the 
hBre1 complex, is abrogated by IFNβ1 treatment.  Knockdown of hBre1 or RNF40 
partially restores growth of HAdV E1A ∆4-25 in the presence of IFNβ1.  
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dependent on this modification at ISGs (Figure 2.14), including H3 K4 and K79 
trimethylation (Figure 2.10).  Similarly to what we have observed with H2B-ub, E1A  
globally alters H3-K18 acetylation by targeting several cellular histone 
acetyltransferases to alter cell growth (Ferrari et al., 2008).  Clearly the versatile E1A 
protein has evolved to exploit interactions with cellular chromatin modifying enzymes 
as a mechanism to efficiently reprogram transcription in the infected cell. 
 Wild-type HAdV is impervious to type I IFN in ex vivo experiments and it is 
known that this virus encodes multiple proteins that counteract the activities of specific 
IFN induced antiviral pathways (Thimmappaya, Weinberger, Schneider, & Shenk, 
1982; Weitzman & Ornelles, 2005).  Each of these known viral countermeasures is 
produced later in infection than E1A.  As E1A is the first protein expressed during an 
HAdV infection, it likely represents the first line of defence against the IFN response.  
In order to establish if the interaction of E1A with the hBre1 contributes to evading the 
type I IFN response, we tested the effects of IFN on growth of WT HAdV and a mutant 
lacking residues 4-25 of E1A. As expected, IFN treatment had no effect on growth of 
WT HAdV.  Although the mutant virus lacking residues 4-25 of E1A grew more poorly 
than WT virus, its growth was completely abrogated by IFN treatment (Figures 2.12, 
14). These growth characteristics confirm that a virus lacking the ability to bind hBre1 
and interfere with H2B-ub is hypersensitive to IFN.  Importantly, knockdown of hBre1, 
RNF40 or both hBre1 and RNF40 simultaneously prior to HAdV infection partially 
restored growth of the ∆4-25 virus in the presence of IFN (Figures 2.12, 14).  Thus, 
knockdown of the hBre1 complex genetically complements the inability of this mutant 
virus to target hBre1 and abrogate the IFN response.  Furthermore, these experiments
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Figure 2.13.  Growth of a mutant adenovirus unable to bind the hBre1 at 48 hours only.  
A549 cells were treated with control siRNA or siRNA specific to hBre1, RNF40 or both 
in combination prior to infection with WT virus (MOI of 5) or HAdV E1A ∆4-25 (MOI 
of 20). Infected cells were treated with or without IFNβ1.  Cells were collected at various 
time points up to 48 hrs post infection to prepare virus lysates.  Production of infectious 
progeny virus was quantitatively assayed by plaque formation of on HEK 293 cells.  
Here, data from Figure 2.6 is shown as a bar graph at 48 hrs only.  Growth of WT HAdV 
is unaffected by IFNβ1 treatment, whereas growth of HAdV E1A ∆4-25, which is unable 
to target the hBre1 complex, is abrogated by IFNβ1 treatment.  Knockdown of hBre1 or 
RNF40 partially restores growth of HAdV E1A ∆4-25 in the presence of IFNβ1.  Data 
significantly different WT virus untreated with IFN within siRNA treatment groups is 
indicated (*P<0.01).  Error bars represent +/- SD.   
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confirm the biological significance of the hBre1 complex in the IFN mediated anti-viral 
response.  
It was recently reported that the N2 protein of influenza H3N2 contributes to 
suppression of the innate immune response by targeting the PAF1 transcriptional 
elongation complex (Marazzi et al., 2012).  Although the PAF1 complex does not 
contain any enzymatic activities that directly modify chromatin, it plays a role in 
recruiting the hBre1 complex to enhance H2B-ub, transcriptional elongation and H3K4 
methylation (Kim et al., 2009).  Although the effect of influenza N2 on H2B-ub is not 
currently known, its interference with PAF1 function will likely reduce H2B-ub, 
similarly to what we observed with E1A.  Thus, adenoviruses, influenza A and 
potentially other viruses have independently evolved mechanisms to interfere with the 
innate immune response by antagonizing hPTMs required for ISGs expression.  This 
convergence of function highlights the importance of chromatin modification in the 
regulation of the type I IFN response. 
hBre1 has also been suggested to function as a tumour suppressor gene (Blank et 
al., 2012; Kim et al., 2009; Moyal et al., 2011).  This is intriguing, as the type I IFN 
response is important in resisting cancer, as well as in controlling infection.  Indeed, 
many cancers lose the ability to respond to IFN (Domschke et al., 2009; Hirsch, Caux, 
Hasan, Bendriss-vermare, & Olive, 2010; Krishnamurthy, Takimoto, Scroggs, & 
Portner, 2006; Marozin et al., 2008) and the importance of immune evasion has been 
formally acknowledged by inclusion in the recently revised list of the hallmarks of 
cancer (Hanahan & Weinberg, 2011).  Our data demonstrating that loss of hBre1 
function confers a loss of IFN responsiveness may provide some mechanistic insight
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Figure 2.14. The hBre1 complex is involved in the transcription of interferon stimulated 
genes (ISGs) and E1A blocks this process by disrupting the interaction between hBre1 
and Ube2b.  Exposure to type I IFN or the innate immune response to virus infection 
results in the recruitment of the hBre1 complex the transcribed regions of ISGs.  Here, 
the catalytically active hBre1 complex monoubiquitinates H2B at K120 resulting in the 
efficient transcription of ISGs.  To counteract this innate immune defence during virus 
infection, HAdV produces the E1A protein, which binds to hBre1, inhibiting the binding 
of Ube2b to the hBre1 complex.  This results in a loss of Ube2b occupancy at the ISG, a 
loss of monoubiquitination of H2B within the chromatin of ISGs and a subsequent lack 
of ISG transcription.  Blockade of this hPTM by the viral E1A protein abrogates the 
large scale changes in cellular gene expression induced by the IFN innate immune 
response.  
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 into its putative role as a tumour suppressor (Shema et al., 2008). 
 In summary, our studies of E1A have led to uncovering an essential role for the 
hBre1 complex in the type I IFN response, which is summarized in Figure 2.7.  The type 
I IFN induced transcriptional program is comprised of >300 ISGs and the establishment 
of this antiviral state is accompanied by a local increase in H2B-ub at each ISG that 
collectively leads to a readily detectable global increase in H2B-ub.  Mechanistically, 
we show that this hPTM requires the recruitment of the hBre1 complex to ISGs, 
resulting in additional hPTM modifications and culminating in efficient IFN induced 
gene expression. We also identify a unique and elegant mechanism by which a viral 
oncoprotein subverts the type I IFN mediated cellular antiviral response by specifically 
antagonizing this hPTM.  This work also exemplifies how studying interactions between 
viruses and their hosts can provide mechanistic insight into fundamental biological 
processes. 
 
2.4 Experimental Procedures 
2.4.1 Cell lines and plasmids 
Human adenocarcinoma A549 and human fibrosarcoma HT1080 cells were grown at 
37oC, 5% CO2 in DMEM (Multicell) and supplemented with 10% fetal bovine serum 
(Gibco).  Plasmids were transfected into HT1080 cells using Superfect reagent (Qiagen) 
following the manufacturer's recommendations.  Transfection efficiency was typically, 
60-70%.  After 24 hours in culture, transfected cells were used for experimentation.  
hBre1 and RNF40 were cloned as a myc tag fusion into pCAN-myc.  Ube2b was cloned 
as an HA tag fusion into pcDNA4. 
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2.4.2 Quantitative RT-PCR 
Total RNA was prepared with Trizol extraction (Invitrogen).  A total of 1μg of RNA was 
reverse transcribed into cDNA by random priming using the One step RT-PCR kit 
(Qiagen) following the manufacturers' instructions.  Quantification of cDNA was done 
using SYBR-Green supermix for real-time qPCR (MyIQ, BioRAD) with oligonucleotide 
sequences that specifically recognize GAPDH, IFITM1, IFNβ1, IRF9, Mx1, OA2, and 
OA4.  GAPDH was used as a control for total cDNA.  Controls without reverse 
transcriptase were done for each RNA sample alongside the cDNA control.  Results were 
normalized to the GAPDH and uninfected sample.  The oligonucleotide sequences are 
listed in Table 2.1. 
 
2.4.3 RNAi knockdown 
Downregulation of hBre1 and RNF40 was performed using Silencer Select siRNA 
(Ambion).  siRNA was delivered to cells via transfection with silentfect (BioRad) 
following the manufacturer’s instructions, 3 hours after seeding cells, for a period of 48 
hours.  A scrambled siRNA was used as a control. 
 
2.4.4 Virus and type I interferon treatment of cells 
Cells were infected with human adenovirus (HAdV5) wild type (dl309), or a panel of 
HAdV containing the indicated E1A deletion mutations: ΔE1A (dl312), E1A Δ4-25 
(dl1101), E1A Δ26-35 (dl1102), E1A Δ30-49 (dl1103) (1).  HAdV was used at a 
multiplicity of infection (MOI) of 5 pfu/cell.  Myxoma was used at an MOI of 20.  Cell 
cultures were infected at 50% confluence and left for 16 hours.  Virus infection was 
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Table 2.1:  A List of Oligonucleotide Primers used in this chapter. 
Target Region Location Forward Reverse Size Tm 
IFITM1 Transcript 560-640 AGCCGCCCATAGCCTGCAAC CAAGGGGGCAGGGGCAACAG 81 60 
IFNβ1 Transcript 185-306 AGTGTCAGAAGCTCCTGTGGCAA TGCGGCGTCCTCCTTCTGGA 122 60 
IRF9 Transcript 902-1010 TTCCCCAAGCCTGGCCCACT GGCAAAGGCGCTGCACGAAG 109 60 
GAPDH Transcript 566-644 ACTGCTTAGCACCCCTGGCCAA ATGGCATGGACTGTGGTCATGAGTC 79 60 
Mx1 Transcript 58-184 GGCCCGTGTTTGCAGGACCA GGGTCAACCGGCAACCCCAG 127 60 
OAS1 Transcript 1170-1273 AGACCGACGATCCCAGGAGGT TGGGGTGGATGCTGCCTGGA 104 60 
OAS2 Transcript 2075-2206 GGGTGGAGGGGACCGTTGGT CCTGGTGTCTGCATTGTCGGC 132 60 
IFITM1 Promoter -(353-254) ATTAATAATTGCAGGCCCACC CTGAGTAGCAGAAGGGAGCCC 101 60 
IFNβ1 Promoter -(358-229) CTACAGTCAGTAGAATCCACGG AAATTGTAAAACAAGACTTGGG 129 62 
IRF9 Promoter -(383-258) TTGGTGGTCCTTCTTCCTGCC TCCTTCCTGGTCCTGAGTCC 125 65 
GAPDH Promoter -(357-265) TTCGCCCCAGGCTGGATGG AGGCGGAGGACAGGATGGC 126 66 
Mx1 Promoter -(307-174) CCTTGAGGACCAAAAGCGACC 
TTATTAGAAATGAACGGTCCGG
GG 134 66 
OAS1 Promoter -(281-151) GCAGTGGGCATGTATTGCTGG CTGGAAATGCATTTTAACCTCC 130 64 
OAS2 Promoter -(410-265) AATCATCAAGCTAATCCTACGAG CTAAACAGCCTCTAGAACCCC 145 62 
Nup107 Transcript  ATGGACAGGCGTGGCTTCGG CGGGTGTCTCAGTAGGCTTCG 225 62 
SMARC
E1 Transcript  GCATTACGATTCCAAAGCCTC CAGTGGCTGTGTGCTTCATTG 414 60 
Slc22a18 Transcript  ATCAACAGGACTTTTGCCCC  Golding et al. 2011 ACAGAATCTAGGCCCAGTG 227 58 
P57kip2 Transcript  GCCAATGCGAACGACTTC Golding et al. 2011 
TACACCTTGGGACCAGCGTACT
CC 364 58 
Blm Transcript 4017-4131 CCGGAAGAAGTGCCGCTGAGG 
GACCTTTGGGAGGCTGGCATCT
T 115 59 
Ccnb1 Transcript 836-1012 CGGGAAGTCACTGGAAACAT AAACATGGCAGTGACACCAA 177 55 
Mcm3 Transcript 47-148 CGGGGTGGAGTCATCCTGGG CGCAGCTCCACATCGTCC 102  
Fhl2 Transcript 33-112 GGGGTTTCTCGAGGGCGGGA GACTCCCGGACGGGGCTGG 98 60 
Lasp2 Transcript 278-332 GGGAACAGGACGCGCGTGAG CGGGCGCAGTTGGGGTTCAT 74 60 
HoxA10 Transcript  Shema et. al. 2008    
fosL2 Transcript  Shema et. al. 2008    
P53 Transcript  Shema et. al. 2008    
E4 orf3 Transcript  GTAGAATTCATGATTCGCTGCTTGAGGCTG 
GATGTCGACTTATTCCAAAAGA
TTATCCAAAACCTC 306 65 
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found to be near 100% by fluorescence microscopy under these conditions using virus 
expressing GFP.  Interferon β1 (IFNβ1) (Cedarlane 11420-1) was added at 1 unit/mL to 
the cell media for 16 hours.  In co-treatment experiments, cells were first infected with 
HAdV at an MOI of 5 for 4 hours before the addition of 1 unit/mL of IFNβ1 for an 
additional 14 hours.  Subconfluent cells were collected for further experimentation. 
 
2.4.5 Acid extraction of histones 
4x105 cells were collected after treatment and lysed with NP40 lysis buffer (0.5%NP-40, 
150mM NaCl, 50mM Tris pH 7.8).  Cells were pelleted and pellets were then treated 
overnight with 0.1 M HCl.  Protein concentrations were then determined using the 
BioRad protein assay reagent using BSA as a control after neutralizing the HCl. 
 
2.4.6 Western blotting and co-immunoprecipitation 
Cells were lysed with NP40 lysis buffer and protein concentrations were determined with 
BioRad protein assay reagent using BSA as a standard.  0.5mg of protein lysate was 
immunoprecipitated with myc or HA hybridoma supernatant or 6µg of anti-mouse IgG 
(Sigma M-7023) at 4oC for 4 hours.  25 µg of protein was kept as 5% input, except as 
noted in the Figure 2.legend of individual blots.  After 3 washes in NP40 lysis buffer, 
complexes were boiled in 25 µL of sample buffer for 5 min.  Proteins were separated on 
NuPage 4-12% Bis-Tris gradient gels (Invitrogen) and transferred onto a nitrocellulose 
membrane (Amersham).  Membranes were blocked in TBS with 0.1% Tween-20 and 5% 
skim milk or BSA and blotted with the indicated primary overnight at 4oC.  Details for 
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 Table 2.2:  A List of Antibodies used in this chapter. 
Reactivity Description Company Cat # 
Mouse IgG Rabbit polyclonal Sigma M-7023 
Actin Rabbit polyclonal Sigma A 2066 
H2B Rabbit polyclonal Millipore 07-371 
H2BK120-monoubiquitination Mouse monoclonal Millipore 05-1312 
H3K4 tri methylation Mouse monoclonal Abcam Ab1012 
H3K9,14 acetylation Rabbit polyclonal Upstate 06-599 
H3K18 acetylation Rabbit polyclonal Abcam Ab1191 
H3K79 tri methylation Rabbit polyclonal Abcam Ab2621 
hBre1/RNF20 Mouse monoclonal Sigma R8904 
IRF3 Rabbit polyclonal Abcam Ab25950 
IRF3(phospho Ser 396) Rabbit monoclonal Abcam Ab76493 
RNF40/hBre1b/RBP95 Mouse monoclonal Sigma R9029 
Ube2b/hRad6 Rabbit polyclonal Bethyl Labs A300-281A 
UbcH6 Rabbit polyclonal Boston Biochem A-630 
9E10 (Myc) Mouse monoclonal In house  
12CA5 (HA) Mouse monoclonal In house  
M73 (E1A) Mouse monoclonal In house  
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the primary antibodies may be found in Table 2.2.  Horseradish peroxidase conjugated 
secondary antibodies were detected using ECL plus western blotting detection system 
(Amersham). 
 
2.4.7 Chromatin immunoprecipitation (ChIP) /ChIP-reChIP 
pproximately 107 cells per sample were cross-linked with 1% formaldehyde at room 
temperature for 10 min.  Cells were washed twice with ice cold PBS and harvested. Cell 
pellets were lysed in 1mL of cell lysis buffer (50 mM Tris-HCl [pH8.1], 10 mM EDTA, 
1% SDS, and a protease inhibitor cocktail (Sigma) on ice for 10 min.  Lysates were 
sonicated in an ultrasonic biorupter bath (Diogenode XL-2006 TO) to yield DNA 
fragment sizes of 200-500 base pairs.  Samples were then centrifuged at 10,000xg for 10 
min.  1 mg of protein was used for ChIP, 100 μg of this was kept as 5% input.  
Supernatants were then diluted 10-fold in dilution buffer (20 mM Tris-HCl [pH8.1], 1% 
Triton X-100, 2 mM EDTA, 150mM NaCl and protease inhibitors) and precleared with 
50 μL of ChIP protein-A Sepharose (50% slurry of protein A-Sepharose containing 2.5 
μg of salmon sperm DNA and BSA /mL) for 50 min at 4oC.  Immunoprecipitations were 
performed overnight at 4oC using 5 μg of the indicated antibody found in Table 2.2.  The 
next morning, 50 μL of ChIP protein-A Sepharose was incubated with each sample for 2 
hrs.  Beads were then washed once each with 500 μL of wash buffer 1 (0.1% SDS, 1% 
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH8.1, 150 mM NaCl), wash buffer II 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH8.1, 500 mM NaCl), 
and wash buffer III (0.25 M LiCl, 1% NP-40, 1% Na-deoxycholate, 1 mM EDTA, 10 
mM Tris-HCl pH8.0) respectively and then washed twice with Tris-EDTA buffer.  
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Immunocomplexes were extracted twice with 150 μL of elution buffer (1% SDS, 0.1 M 
NaHCO3).  For ChIP-reChIP, samples were then rediluted 10x with dilution buffer and 
immunoprecipitation was repeated with a second antibody as indicated (2).  After final 
elution, 12 μL of 5M NaCl was added to the 300 μL pooled elution and incubated at 65oC 
overnight to decrosslink the complexes.  DNA was then purified using Quigen PCR 
purification spin columns.  Conditions for qRT PCR using SYBR Green were as per the 
manufacturers' directions.  Briefly, each 15 μL reaction contained 80 nM oligos and 0.5 
uL of ChIP DNA. 
 
2.4.8 Statistical analysis 
All numerical values represent means + S.E.M.  Each experiment was done in three 
replicates and a representative replicate is shown for each blot.  Statistical significance of 
the differences was calculated using one way Anova and Holm-Sidak to all other 
treatments in the experiment. 
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Chapter 3:  
Viral retasking of hBre1/RNF20 to recruit hPaf1 for 
transcriptional activation 
3.1 Introduction 
Viruses are obligate intracellular pathogens as they require cellular machinery to 
replicate.  Indeed, viruses often subvert the functions of cellular machinery to support 
their life cycle.  Human adenovirus (HAdV) is no exception, and during infection must 
appropriate the host cellular transcriptional apparatus to begin transcription of the viral 
genes necessary to reprogram the cellular environment (Frisch and Mymryk, 2002; 
Ferrari et al., 2009).  This is done in large part by the viral products of Early Region 1A 
(E1A), the first gene transcribed after infection.  The E1A proteins bind and redirect the 
activity of transcriptional regulators to initiate transcription of the HAdV early genes 
(Hearing and Shenk, 1986; Ferrari et al., 2009).  The HAdV 5 E1A mRNA has five splice 
variants. The two largest isoforms, 13S and 12S, encode 289 and 243 residue (R) 
proteins, respectively. These proteins predominate at the early stages of virus infection.  
Sequence alignment of E1A from a variety of HAdVs shows four regions of 
conservation, and have been designated CR1-4 (Avvakumov et al., 2002).  The 289R and 
243R E1A proteins of HAdV 5 are identical except for the presence of an additional 46 
amino acid sequence within the 289R (Pelka et al., 2008).  This unique 46 amino acid 
region encompasses CR3 (Geisberg et al., 1994).  Both the CR3 region and N-terminal 82 
residues of E1A are sufficient to activate transcription when fused to a heterologous 
DNA binding domain (Yousef et al., 2009; Bondesson et al., 1994). Although each region 
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can separately recruit a plethora of transcriptional activators (Stevens et al., 2002; 
Geisberg et al., 1994; Bondesson et al., 1994; Mazzarelli et al., 1997; Grand et al., 1999; 
Duyndam et al., 1996), they function together to recruit cellular transcriptional complexes 
for the activation of viral transcription (Geisberg et al., 1994; Wong and Ziff, 1994; Pelka 
et al., 2008; Ablack et al., 2012).  CR3, specifically, activates transcription through 
interactions with the mediator complex component Med23 (mediator complex subunit 
23) (Stevens et al., 2002; Ablack et al., 2010; Berk, 2005).  CR3 activity is further 
modulated by pCaf (CREBBP-associated factor), Gcn5 (general control of amino-acid 
synthesis, yeast, homolog), p300 (E1A binding protein p300), BS69 (bone morphogenetic 
protein receptor-associated molecule 1) and Sug1 (26S proteasome AAA-ATPase subunit 
RPT6) (Pelka et al., 2009a; Ablack et al., 2010; Hateboer et al., 1995; Grand et al., 1999; 
Pelka et al., 2009b).  Likewise, the N-terminus of E1A interacts with transcriptional 
activators, such as p300, CBP (CREB-binding protein), p400 (E1A binding protein 
p400), pCaf, TBP (TATA binding protein), and TRAAP (transformation/transcription 
domain-associated protein) (Frisch and Mymryk, 2002).  Although there exists a large 
body of research focusing on the role that CR3 plays in virus transcription, the 
requirement for the N-terminus, which is conserved in both the 289R and 243R E1A 
proteins, and the mechanisms through which it cooperates with CR3 to activate viral 
transcription, are poorly understood.  
 Previously, we identified a novel interaction between the N-terminus of HAdV 5 
E1A and hBre1(human BREfeldin A sensitivity)/RNF20 (Ring finger protein 20) 
(Fonseca et al., 2012).  hBre1 is a cellular ubiquitin ligase, which functions in concert 
with the accessory factor RNF40 (Ring finger protein 40) and the Ube2b (Ubiquitin-
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conjugating enzyme E2B) ubiquitin conjugase to monoubiquitinate histone 2B (H2B) 
(Kim et al., 2009; Osley, 2004).  The monoubiquitination of H2B (H2B-ub) is an 
epigenetic mark of genes that are highly transcriptionally active (Shema et al., 2008).  
H2B-ub is a precursor to other activation marks, such as the trimethylation of histone 3 
lysines 4 and 79, which are promoted by the interaction of the hBre1 complex with the 
hPaf1 (human RNA polymerase II associated factor 1) complex (Kim and Roeder, 2009; 
Wood et al., 2003).  During infection, E1A binds to hBre1 and blocks the interaction 
between hBre1 and the catalytic subunit Ube2b.  This specifically antagonizes the ability 
of the hBre1 complex to monoubiquitinate H2B at interferon (IFN) responsive genes 
(Fonseca et al., 2012).  In this way, the interaction of E1A with hBre1 blocks 
transcriptional activation of IFN responsive genes and this contributes to inhibition of the 
cellular innate immune response to HAdV infection via an epigenetic mechanism 
(Fonseca et al., 2012). 
 Here, we investigate whether the interaction of HAdV 5 E1A with hBre1 
influences transcription from the HAdV genome.  We have found that the interaction of 
E1A with hBre1 contributes to the activation of early viral gene expression.  Specifically, 
E1A utilizes hBre1 as a scaffolding protein to recruit the hPaf1 complex to HAdV early 
genes.  This retasking of the hPaf1 complex, which is known to promote RNA 
polymerase II transcription elongation and transcription-coupled histone modifications, 
contributes to E1A mediated activation of HAdV early gene expression.  Thus, in 
addition to antagonizing the ability of hBre1 to function as an E3 ubiquitin ligase 
involved in transcriptional activation of the innate immune response, the interaction of 
E1A with hBre1 serves a second distinct purpose as a novel means of enhancing viral 
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gene transcription by recruiting the hPaf1 complex. 
3.2 Results 
3.2.1 hBre1 contributes to Gal4 mediated transcriptional activation by the N-
terminus.   
We previously showed that the N-terminus of E1A interacts with the cellular ubiquitin 
ligase hBre1 (Fonseca et al., 2012).  To determine if hBre1 influences transcriptional 
activation by the N-terminus of E1A, human U-2 OS osteosarcoma cells were treated 
with either a control (Ctrl) siRNA or one of 4 hBre1 specific siRNAs.  Cells were then 
transfected with a constitutive β-galactosidase reporter, a Gal4 responsive luciferase 
reporter and a vector expressing the Gal4 DNA binding domain (DBD) alone or Gal4 
DBD fused to the N-terminus of E1A.  As an additional control, cells were similarly 
transfected with a vector expressing the Gal4 DBD fused to E1A CR3. E1A CR3 also 
functions as a strong transcriptional activation domain, but does not interact with hBre1.  
Luciferase activities were measured and results were normalized to β-galactosidase 
activity.  The effects of siRNA treatment were calculated as a relative fold change with 
respect to cells transfected with a vector expressing the Gal4 DBD alone.  Treatment with 
each of the 4 hBre1 specific siRNAs resulted in decreased hBre1 expression, which was 
accompanied by a decrease in E1A N-terminal dependent transcriptional activation 
(Figure 3.1).  Based on this result, we used hBre1 siRNA 3 for further experiments.  In 
contrast to its effects on transactivation by the N-terminus of E1A, knockdown of hBre1 
had only modest effects on transcriptional activation by E1A CR3.  These data suggest 
that hBre1 is involved transcriptional activation mediated by the N-terminus of E1A, but 
not by CR3. 
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Figure 3.1.  The N-terminus of E1A specifically requires hBre1 for full activation of 
transcription.  U-2 OS cells were transfected with a negative control siRNA or 1 of 4 
siRNAs specific for hBre1.  Cells were then transfected with a constitutive β-
galactosidase reporter, a Gal4 responsive luciferase reporter and a vector expressing the 
Gal4 DNA binding domain (DBD) alone, the Gal4 DBD fused to the N-terminus of E1A, 
or the Gal4 DBD fused to E1A CR3.  Luciferase activity was measured.  Results were 
normalized to β-galactosidase activity and siRNA treated groups were set as a fold 
change to the Gal4 only transfected counterpart.  A statistically significant decrease from 
control siRNA treatment is indicated (* P<0.01). n=3 
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Figure 3.2. Kinetics of virus infection under the conditions used for all experiments. (A) 
Viral genome replication is detected at 36 h.p.i.  RT-qPCR was performed on DNA 
collected from the time course of infected cells using primers for the E1A promoter to 
detect copies of the viral genome and GAPDH to detect copies of the cellular genome. 
Results of WT infected cells were normalized to ΔE1A HAdV and set as fold to the 
cellular genome via the GAPDH promoter.  (B) HAdV late gene expression is not 
detected until 36 h.p.i. A549 cells were infected at an MOI of 5 with WT or ΔE1A 
HAdV. Cells were collected at the indicated time points and RNA and DNA were 
collected. RT-qPCR was performed for the HAdV early transcripts E1A and the late 
genes E2l and L5, and normalized to GAPDH. Fold change to GAPDH was plotted. (C) 
HAdV late gene protein expression is detected at 48 h.p.i. A549 cells infected with WT 
virus were collected after 20 h.p.i. and protein was detected via western blotting with the 
indicated antibodies (E1A represents early gene expression and hexon represents late 
gene expression). n=2 
110
100
1000
10000
6 12 18 24 36 48 60 72
F
o
ld
 I
n
c
re
a
s
e
0
200
400
600
800
1000
1200
1400
1600
6 12 18 24 36 48 60 72
E1A
L5
E2L
F
o
ld
 I
n
c
re
a
s
e
h.p.i
IB-αE1A
IB-αhexon
12 24 36 48 60h.p.i.
IB-αActin
h.p.i
A
B
C
E1A promoter
127
128 
 
3.2.2 E1A requires hBre1 and likely p300/CBP to fully activate transcription of viral 
early genes.   
To determine if the hBre1 complex is required for E1A dependent activation of viral 
early gene expression, human A549 lung epithelial cells were treated with Ctrl siRNA or 
siRNA specific to either hBre1 or the hBre1 complex member RNF40 and were then 
infected with either wildtype (WT; dl309) HAdV or a series of HAdV E1A deletion 
mutants at a multiplicity of infection (MOI) of 5.  These viruses express both the 289R 
and 243R E1A proteins.  cDNA was prepared from cells collected 20 hours post infection 
(h.p.i).  Under these conditions of infection, this time point precedes the onset of viral 
late gene transcription and expression, as well as amplification of the viral genome 
(Figure 3.2).  The expression of a panel of HAdV early genes known to be activated by 
E1A was determined by quantitative real time PCR.  Knockdown of hBre1 did not 
consistently reduce expression from the viral E1A or E1B transcription units over the 
panel of viruses (Figure 3.3A,B).  However, mRNA levels were significantly decreased 
from both the E3 and E4 transcription units in cells treated with hBre1 specific siRNA 
(Figure 3.3C and D).  In contrast, treatment with siRNA specific for the RNF40 
component of the hBre1 complex did not significantly decrease mRNA levels from any 
of the HAdV early genes (Figure 3.3, all panels).  This result was unexpected, as RNF40 
is essential for monoubiquitination of H2B by the hBre1 complex (Kim et al., 2009).  
Infection with a virus containing a deletion of E1A that is unable to bind hBre1 (E1A Δ4-
25), also showed a reduction in transcription of E3 and E4, but not E1A and E1B (Figure 
3.3).  Interestingly, the decreased early gene expression observed with this mutant was 
not further exacerbated by knockdown of hBre1.  This suggested the inability of the E1A  
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Figure 3.3.  hBre1 contributes to E1A mediated activation of E3 and E4 expression 
during infection with HAdV.  A549 cells were treated with Ctrl siRNA, siRNA specific 
to RNF40 or siRNA specific for hBre1 (Shown in the inset panel) and infected at an MOI 
of 5 with WT HAdV, or a series of HAdV containing the indicated deletions within the 
N-terminus of E1A (Shown in the inset panel).  RT-qPCR was performed with a panel of 
HAdV early genes, normalized to GAPDH and fold change to uninfected Ctrl siRNA 
treated cells was plotted.  Results for the HAdV E1A (A), E1B (B), E3 (C), and E4 (D) 
transcription units are shown. A statistically significant decrease from siCtrl is indicated 
(* P<0.01). n=3 
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Δ4-25 mutant to bind hBre1 and the knockdown of hBre1 might have redundant effects 
on E1A dependent transcription of E3 and E4 (Figure 3.3C and D).   
 A reduction in the transcriptional activation of E3 and E4 was also observed 
during infection with virus containing E1A deletions in adjacent regions not required for 
interaction with hBre1 (E1A Δ26-35, E1A Δ30-49; Figure 3.3C and D). In contrast to 
E1A Δ4-25, transcription of E3 and E4 during infection with these mutants was further 
decreased by knockdown of hBre1 (Figure 3.3C and D).  Taken together, these results 
suggest that, while hBre1 is specifically targeted by E1A to enhance transcriptional 
activation of E3 and E4, other factors bound at adjacent regions of E1A also contribute to 
full transcriptional activation.   
 It should be noted that residues 4-25 of E1A are also required for interaction with 
p300 and CBP as well as hBre1 (Egan et al., 1988; Mymryk et al., 1992).  p300/CBP may 
also play a role in E1A-dependent transactivation as the mutant lacking residues 30-49, 
which are also required for p300/CBP interaction (Egan et al., 1988; Mymryk et al., 
1992) but not hBre1 binding (Fonseca et al., 2012), also shows a reduction of E3 and E4 
expression (Figure 3.3C, 2D).  
 
As hBre1, but not RNF40 is required for maximal E1A dependent activation of E3 and 
E4 expression (Figure 3.3), we next determined whether hBre1 complex members or 
H2B-ub could be detected on the E3 and E4 promoters.  A549 cells were infected with 
WT HAdV or a HAdV containing a deletion of E1A (ΔE1A) at an MOI of 5.  Chromatin 
3.2.3 hBre1 is recruited to HAdV early genes by E1A, but this does not lead to H2B 
monoubiquitination.   
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Figure 3.4.  E1A recruits hBre1 to HAdV early gene promoters, but HAdV chromatin is 
not monoubiquitinated by hBre1.  A549 cells were infected with WT HAdV or ∆E1A 
HAdV for 20 hours.  Chromatin immunoprecipitation (ChIP) was then performed with 
antibodies specific for the indicated proteins. DNA was probed via qRT-PCR for the 
presence of HAdV early gene promoters.  Data was normalized to ∆E1A HAdV and a 
non-specific antibody control.  Occupancy by RNA pol II and E1A (A), hBre1 complex 
members (B), and the indicated histone post-translational modifications (C) at HAdV 
early gene promoters are shown.  In B, a statistically significant increase from mouse 
antibody ChIP is indicated (* P<0.01). n=3 
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immunoprecipitation (ChIP) was then performed using an antibody control, E1A specific 
antibody, RNA polymerase II (RNA pol II) specific antibody, and antibodies specific to 
hBre1 complex members hBre1, RNF40, and Ube2b.  As expected (Rasti et al., 2006), 
E1A was present at all HAdV early gene promoters and this correlated with the 
transcriptional status as determined by occupancy of RNA pol II (Figure 3.4A).  E1A was 
not detected on the cellular GAPDH (glyceraldehyde-3-phosphate dehydrogenase) 
promoter, as has been previously published (Fonseca et al., 2012; Ferrari et al., 2008).  
Similarly, hBre1 and RNF40 were specifically associated with the promoters of the 
HAdV early genes E2e, E3, and E4, but not with E1A or E1B (Figure 3.4B and 3.5).  In 
contrast, Ube2b, the catalytic member of the hBre1 complex involved in H2B 
monoubiquitination, was not recruited to the HAdV genome. Given that RNF40 is not 
required for transcriptional activation of HAdV early genes, and Ube2b is not present on 
their promoters, it seems unlikely that the hBre1 complex could perform its best 
characterized function, the monoubiquitination of H2B.  This was confirmed by ChIP 
analysis, which demonstrated that H2B-ub was not present on viral chromatin at the E3 
and E4 promoters (Figure 3.4C).   Despite an absence of H2B-ub, marks of 
transcriptional activation such as H3K18 acetylation, and H3K4 and K79 trimethylation 
were detected by ChIP on the E3 and E4 promoters (Figure 3.4C), which is consistent 
with the presence of RNA pol II (Figure 3.4A).  
 
3.2.4 hPaf1 contributes to transcriptional activation by the N-terminus of E1A, but 
not by CR3.   
In addition to its function in H2B monoubiquitination, hBre1 interacts with several other 
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Figure 3.5. HAdV early genes E1A, E1B, and E2e display varied hPTM states which do 
not include H2B-ub association.  A549 cells were infected with WT HAdV or ∆E1A 
HAdV for 20 hours.  Chromatin immunoprecipitation (ChIP) was then performed with 
antibodies specific for the indicated histone or hPTMs. DNA was probed via qRT-PCR 
for the presence of HAdV early gene promoters E1A, E1B or E2e.  Data was normalized 
to ∆E1A HAdV and a non-specific antibody control. n=3 
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complexes involved in transcriptional regulation (Lee et al., 2007; Wood et al., 2003; 
Kim and Roeder, 2009; Hahn et al., 2012).  To determine if any of these hBre1 
interacting complexes were similarly required for E1A dependent transcriptional 
activation, U-2 OS cells were treated with siRNA specific to hPaf1, SetD  (SET domain 
containing) 1A, SetD1B, MLL (myeloid/lymphoid or mixed-lineage leukemia) 2, or 
MLL3 & 4.  Cells were then transfected with a constitutive β-galactosidase reporter, a 
Gal4 responsive luciferase reporter and a vector expressing Gal4 or Gal4 fused to the N-
terminus of E1A.  Gal4 fused to E1A CR3 was again used as a control, as it functions as 
a strong transactivator, but does not bind to hBre1.  Knockdown of hPaf1 did not affect 
hBre1 expression (Figure 3.6, inset), but nevertheless resulted in significant decreases in 
transcriptional activation by the N-terminus of E1A, but not CR3 (Figure 3.6).  This 
result is similar to what was observed for knockdown of hBre1 (Figure 3.1) and suggests 
that the hPaf1 complex is specifically recruited by the N-terminus of E1A to enhance 
transcriptional activation.  None of the other knockdowns specifically reduced activation 
by the N-terminus of E1A as they also reduced activation by CR3, which does not bind to 
hBre1 (Figure 3.6).   
 
3.2.5 hPaf1 is recruited to the viral E3 and E4 gene promoters in an E1A and hBre1 
dependent manner.   
To determine whether hPaf1 is recruited to the HAdV genome, we performed ChIP 
analysis. A549 cells were infected with WT HAdV and a series of HAdV containing 
deletions in E1A at an MOI of 5.  ChIP was then performed using an antibody control 
and a hPaf1 specific antibody.  hPaf1 was found to specifically localize to the E2e, E3 
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Figure 3.6. The N-terminus of E1A, but not CR3 requires hPaf1 for efficient 
transcriptional activation.  U-2 OS cells were transfected with a negative Ctrl siRNA or 
siRNAs specific for known hBre1 interacting proteins.  Cells were then transfected with a 
constitutive β-galactosidase reporter, a Gal4 responsive luciferase reporter and a vector 
expressing the Gal4 DBD alone, Gal4 DBD fused to the N-terminus of E1A, or Gal4 
DBD fused to E1A CR3.  Luciferase activity was measured.  Results were normalized to 
β-galactosidase activity and siRNA treated groups were set as a fold to the Gal4 only 
transfected counterpart. A statistically significant decrease from Ctrl siRNA treatment is 
indicated (* P<0.01). n=3 
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and E4 viral early gene promoters in an E1A dependent manner, and this required the 
same region of E1A (residues 4-25) necessary for interaction with hBre1 (Figure 3.7A 
and B).  Reduced hPaf1 occupancy of the E3 and E4 promoters was also observed during 
infection with virus expressing E1A lacking residues 30-49 of E1A. Although this 
reduction was not as substantial as with the Δ4-25 mutant, the Δ30-49 mutant retains 
binding to hBre1, suggesting that other factors such as p300/CBP may influence hPaf1 
recruitment.  ChIP analysis did not detect hPaf1 within the E3 and E4 gene transcribed 
regions (Figure 3.7A), the E1A and E1B promoters (Figure 3.7B), or IFN responsive 
genes (Figure 3.8) during infection suggesting a specific recruitment and localization to 
the E2e, E3 and E4 promoters.  Furthermore, ChIP reChIP experiments demonstrated that 
hPaf1 co-occupied the E2e, E3 and E4 promoter regions with both hBre1 and E1A 
(Figure 3.7C) but did not show any co-localization with either hBre1 or E1A at E1A or 
E1B promoters (Figure 3.9A). This colocalization on HAdV early genes suggests that 
E1A, by binding hBre1, is recruiting hPaf1 to participate in the transcriptional activation 
of the viral E3 and E4 early genes.  
 Next, we tested whether hPaf1 recruitment to HAdV early genes required hBre1.  
A549 cells were treated with either a non-specific control siRNA or an siRNA specific to 
hBre1 and infected with WT HAdV at an MOI of 5.  ChIP was then performed using an 
antibody control or an antibody specific to hPaf1.  Knockdown of hBre1 substantially 
affected hPaf1 recruitment to the E2e, E3 and E4 promoters during HAdV infection, but 
not E1A, E1B or GAPDH (Figure 3.9B).  In contrast, siRNA knockdown of hPaf1 did 
not reduce hBre1 recruitment to the HAdV genome during HAdV infection (Figure 
3.9B). These results indicate that E1A is utilizing hBre1 as a scaffold to recruit hPaf1 to 
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Figure 3.7. E1A recruits hPaf1 to HAdV early gene promoters via hBre1.  (A, B) hPaf1 is 
localized at the E2e, E3 and E4 promoters. A549 cells were infected with WT HAdV, 
∆E1A HAdV or HAdV containing deletions within E1A for 20 hours.  Chromatin 
immunoprecipitation (ChIP) was performed with the indicated antibodies and DNA was 
probed via qRT-PCR for the presence of HAdV early gene promoters or transcribed 
regions.  hPaf1 localization requires residues 4-25 of E1A and s found on the E2e, E3 and 
E4 but not the E1A or E1B promoter regions. A statistically significant decrease from 
WT in A is indicated (* P<0.01).  (C) hPaf1 colocalizes with E1A and hBre1 on the E3 
and E4 promoters.  hPaf1 ChIP was followed by re-ChIP with either hBre1 or E1A 
specific antibodies to determine co-occupancy.  Data was normalized to ∆E1A HAdV 
and a non-specific antibody control.  (D and E)  hPaf1 recruitment to the E3 and E4 
promoter requires hBre1.  A549 cells were treated with a non-specific siRNA, or siRNA 
specific for hBre1 (D), or hPaf1 (E) prior to virus infection.   ChIP assays were then 
performed using hBre1 or hPaf1 specific antibodies.  hPaf1 and hBre1 occupancy was 
then determined at the HAdV E3 and E4 promoters as described above. n=3 
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the E3 and E4 promoters. Further, hPaf1 was shown to interact with E1A by co-
immunoprecipitation. This interaction was dependent on hBre1 expression, as 
knockdown of hBre1 reduced hPaf1 co-association with E1A (Figure 3.9C). 
 
3.2.6 hPaf1 is required for expression of the viral E3 and E4 transcription units.  
To determine if hPaf1 is involved in the transcriptional activation of HAdV early genes, 
A549 cells were treated with control or hPaf1 specific siRNAs and infected with WT or 
ΔE1A virus.  Knockdown of hPaf1 compared to control siRNA treatment caused a 
reduction in the ability of WT virus to activate expression of the viral E2e, E3 and E4 
(Figure 3.10A), but not the E1A and E1B early genes during infection (Figure 3.10A).  
Thus, hPaf1 knockdown affected the expression of same subset of early genes affected by 
knockdown of hBre1 (Figure 3.3).  These data confirm that hPaf1 is involved in E1A 
dependent activation of viral E2e, E3 and E4 gene expression.   
 
3.2.7 Recruitment of hPaf1 is required for H3K4 and H3K79 tri-methylation of the 
HAdV E3 and E4 promoters.   
Recruitment of the hPaf1 complex to a transcriptional template has been reported to be 
necessary for several histone post-translational modifications associated with active 
transcription, including trimethylation of H3K4 and H3K79 (Kim et al., 2009; Mohan et 
al., 2010).  To determine if hPaf1 is required for the observed E1A dependent increase in 
H3K4 and H3K79 tri-methylation at the viral E3 and E4 promoters, A549 cells were 
infected as before with WT or ΔE1A virus and ChIP was performed using antibodies 
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Figure 3.8.  hPaf1 is excluded from IFN regulated genes during WT HAdV infection. 
ChIP assays were performed on A549 cells 20 hours after infection with the indicated 
viruses at a MOI of 5.  ChIP was then performed using a control anti-mouse antibody or 
antibodies specific for hBre1, Ube2b, E1A, or hPaf1.  hBre1, Ube2b and hPaf1 associate 
with IFN regulated gene bodies during IFN stimulating conditions (ΔE1A virus 
infection). In contrast, in the presence of E1A, Ube2b and hPaf1 are excluded from IFN 
stimulated gene bodies (WT virus infection). A statistically significant decrease from 
ΔE1A infected is indicated (* P<0.01). n=3 
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specific for H3K4 or H3K79 trimethylation.  Knockdown of hPaf1 significantly reduced 
H3K4 and H3K79 trimethylation at the viral E2e, E3 and E4 promoters, but not the E1A, 
E1B or GAPDH promoters (Figure 3.10B). This suggests that hPaf1 plays an essential 
role in generating these two histone modifications at the E3 and E4 promoters, but not the 
E1A promoter. 
 
3.2.8 The E1A proteins from multiple HAdV types target hBre1. 
Although it is known that the HAdV 5 E1A protein binds hBre1, it is not known whether 
this interaction is a feature of all E1A proteins. To determine if the interaction with hBre1 
is evolutionarily conserved among the different HAdV types, we co-transfected human 
HT1080 fibrosarcoma cells with hBre1 and a representative E1A from six different 
HAdV groups with a C-terminal GFP.  Co-immunoprecipitation was performed on 
lysates by immunoprecipitating the representative E1As with GFP antibody and any co-
precipitated hBre1 was detected with hBre1 specific antibody.  hBre1 interacted strongly 
with all of the E1A proteins tested, with the exception of HAdV 12 (Figure 3.11A).  The 
conservation of the E1A-hBre1 interaction across multiple HAdV species suggests that 
targeting of hBre1 is an important aspect of E1A function.  
 
3.2.9 hBre1 and hPaf1 are required for transcriptional activation by the E1A proteins 
of multiple HAdV types.   
The evolutionary conservation of the E1A-hBre1 interaction (Figure 3.11A) suggested 
that there could also be an evolutionary conservation of E1A-hBre1 function as well.  To 
test this, U-2 OS cells were treated with non-specific siRNA, hBre1 specific siRNA or 
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Figure 3.9. hPaf1 recruitment to the E2e, E3 and E4 promoters requires E1A and hBre1 
and the interaction of E1A with hPaf1 requires hBre1.  (A) hPaf1 ChIP was followed by 
re-ChIP with either hBre1 or E1A specific antibodies to determine co-occupancy at the 
E1A and E1B promoters.  Data was normalized to ∆E1A HAdV and a non-specific 
antibody control.  hPaf1 is not co-associated with E1A and hBre1 at these promoters. (B) 
hPaf1 recruitment to the E2e, E3 and E4 promoters requires hBre1.  A549 cells were 
treated with a non-specific siRNA, or siRNA specific for hBre1, or hPaf1 prior to virus 
infection.   ChIP assays were then performed using hBre1 or hPaf1 specific antibodies.  
hPaf1 and hBre1 occupancy was then determined at the HAdV E1A, E1B, E2e, E3 and 
E4 promoters as described above. A statistically significant decrease from Ctrl siRNA 
treatment is indicated (* P<0.01) for B. (C) hPaf1 interacts with E1A and this is hBre1 
dependent. A549 cells were treated with Ctrl or hBre1 specific siRNA and infected with 
WT or ΔE1A virus. Cells were collected after 20 hours. Lysates were 
immunoprecipitated with anti-E1A antibody and probed for hPaf1. n=2 
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hPaf1 specific siRNA.  Cells were then transfected with a constitutive β-galactosidase 
reporter, a Gal4 responsive luciferase reporter and a vector expressing the Gal4 DBD or 
the Gal4 DBD fused to the N-terminus of E1A.  The results from the luciferase assays 
indicate that activation by the N-terminus of the HAdV 3, 4, 5 and 9 E1A proteins types 
was reduced when either hPaf1 or hBre1 are knocked down (Figure 3.11B).  Thus, the 
E1A proteins from multiple HAdV types appear to utilize both hBre1 and hPaf1 for 
transcriptional activation.   
 
3.3 Discussion 
HAdV E1A is an unusually strong and multifarious regulator of gene expression.  E1A is 
the first protein expressed during viral infection and acts to reprogram cellular gene 
expression, as well as activate viral early gene expression.  As such, E1A serves as a 
paradigm of eukaryotic transcriptional control.  As one particular example, the ability of 
E1A to bind and sequester the p300/CBP acetyltransferases is a well established 
mechanism by which E1A can repress cellular transcription (Jelsma et al., 1989; Horwitz 
et al., 2008a; Ferrari et al., 2009).  We previously demonstrated that HAdV 5 E1A targets 
the cellular hBre1 complex. E1A disrupts the interaction between the hBre1 ligase and 
the Ube2b conjugase, leading to a global reduction in H2B-ub, decreased occupancy by 
hPaf1 and a consequent abrogation of type I IFN dependent gene expression (Fonseca et 
al., 2012) (Figure 3.8).  The interaction of E1A with hBre1 provides a mechanism by 
which E1A antagonizes expression of cellular genes required for the innate immune 
response to viral infection in addition to the sequestration of p300/CBP.  In the present 
work, we have determined that the interaction of E1A with hBre1 is further exploited by 
150 
 
 
 
 
Figure 3.10. hPaf1 is required for expression of the HAdV E2e, E3 and E4 genes during 
infection and chromatin marks associated with active gene expression. (A) Knockdown 
of hPaf1 does not affect E1A and E1B expression, but greatly reduces E3 and E4 
expression during infection. A549 cells were treated with Ctrl siRNA or hPaf1 specific 
siRNA and infected with wildtype (WT) or ΔE1A HAdV.  qRT-PCR was then performed 
for E3 and E4 expression.  Data was normalized to GAPDH and fold was set to the WT 
CTRL siRNA of the same gene. (B)  hPaf1 is required for H3K4 and H3K79 
trimethylation at the E3 and E4 promoters.  ChIP assays were performed on A549 cells 
treated with siRNA as indicated and infected for 20 hours at a MOI of 5.  ChIP was then 
performed using antibodies specific for trimethylated H3K4 or H3K79 and qRT-PCR 
was performed for the indicated HAdV early gene promoter region. A statistically 
significant decrease from Ctrl siRNA treatment is indicated (* P<0.01). n=3 
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the virus to activate expression of the viral E2e, E3 and E4 transcription units.  Thus, 
subversion of the hBre1 complex by E1A results in two distinct and opposite effects: 
inhibition of transcription from cellular IFN responsive genes and activation of viral gene 
expression (Figure 3.12).   
 Our findings here show a novel means by which hBre1 facilitates transcriptional 
activation, specifically via recruitment and modulation by the N-terminus of E1A.  More 
importantly, the contribution made by this interaction is completely independent of the 
known ability of the hBre1 complex to monoubiquitinate H2B.  Indeed, neither the 
Ube2b nor RNF40 components of the hBre1 complex are required for E1A dependent 
activation of viral early gene expression.  This reveals an alternative and unexpected 
method by which hBre1 can activate transcription.  We hypothesized that during 
infection, E1A functionally retasks the catalytically inactive hBre1 complex, converting it 
into a scaffold to recruit additional factors that enhance expression of the viral E2e, E3 
and E4 early gene promoters.  Our results indicate that the outcome of viral retasking of 
the hBre1 complex is the recruitment of the cellular hPaf1 complex.  The hPaf1 complex 
functions as an important regulator of RNA pol II transcriptional regulation, primarily by 
promoting transcription elongation and transcription-coupled histone modifications 
(Tomson and Arndt, 2012).  We demonstrate that hPaf1 was specifically required for 
transcriptional activation by the N-terminus of HAdV 5 E1A (Figure 3.6), was recruited 
to HAdV early genes in an identical pattern to hBre1 and required hBre1 and E1A for this 
recruitment (Figure 3.4 and 3.7). In addition, hPaf1 shared co-occupancy on the viral 
E2e, E3 and E4 promoters with both E1A and hBre1 and was required for efficient 
expression of these genes during infection (Figure 3.7 and 3.10).  In contrast, hPaf1 was 
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Figure 3.11.  hBre1 is a conserved target of the E1A proteins of multiple types of HAdV. 
(A) Evolutionary conservation of hBre1 binding with the E1A proteins of multiple HAdV 
types. HT1080 cells were transfected with hBre1 and either empty control vector, or the 
E1A genes from representative members of the 6 types of HAdV.  E1A was 
immunoprecipitated and Western blots were performed using hBre1 specific antibody or 
HA to detect E1A proteins.  (B) The E1A proteins from several types utilize hBre1 and 
hPaf1 for transcriptional activation.  U-2 OS cells were treated with Ctrl non-specific 
siRNA, or an hBre1 or hPaf1 specific siRNA (shown in the inset panel).  Cells were then 
transfected with a constitutive β-galactosidase reporter, a Gal4 responsive luciferase 
reporter and a vector expressing the Gal4 DBD alone, or Gal4 DBD fused to the N-
terminus of the indicated HAdV E1A.  Luciferase activity was measured.  Results were 
normalized to β-galactosidase activity and siRNA treated groups were set as a fold to the 
Gal4 only transfected counterpart. A statistically significant decrease from Ctrl siRNA 
treatment within the Gal4 fusion group is indicated (* P<0.01). n=3 
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not recruited to the viral E1A and E1B promoters and was also not required for their 
expression (Figure 3.9B, 3.7B and 3.10A), suggesting that additional factors are involved 
in activating expression of these genes. 
 CR3 is known to be the primary activation domain of viral transcription in HAdV 
5 E1A. This is evidenced in that the 289R E1A product activates viral transcription far 
more strongly than the 243R E1A product, which lacks CR3 (Ablack et al., 2010; Berk, 
2005).  Also, CR3 alone is able to activate viral transcription (Ablack et al., 2010; 
Mazzarelli et al., 1997).  However, activation of early gene transcription is greatly 
enhanced by the presence of the N-terminus of E1A (Ablack et al., 2010; Wong and Ziff, 
1994).  This functional cooperation may be mediated in part by the co-recruitment of the 
p300/CBP histone acetyltransferases by the N-terminus and CR3 regions of E1A HAdV 5 
(Pelka et al., 2009b; Wong and Ziff, 1994).  The data presented here suggests that, in 
addition to p300/CBP, the N-terminus also contributes to viral early gene activation by 
recruiting hBre1.  E1A dependent promoter occupancy by hBre1 in turns recruits the 
hPaf1 complex and in turn recruits additional factors that further modify viral chromatin, 
including the appearance of transcriptional activation marks such as H3K4 and H3K79 
trimethylation (Figure 3.10B).  
 The N-terminus of the E1A proteins from multiple HAdV species interact with 
hBre1 (Figure 3.11A).  This preservation of E1A interaction suggests a strong 
evolutionary conservation of functional utility.  Knockdown of hBre1 or hPaf1 reduced 
transactivation by HAdV3, 4 and 9 (Figure 3.11B), corroborating that their conserved 
ability to bind hBre1 contributes to transcriptional activation, as we observed with HAdV 
5 E1A.  Although HAdV 40 E1A bound hBre1, knockdown of hBre1 or hPaf1 did not 
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Figure 3.12.  The interaction of E1A with hBre1 serves two completely different 
purposes during HAdV infection.  By disassociating the catalytically active Ube2b 
component from the hBre1 complex, E1A inhibits H2B monoubiquitination and 
suppresses transcription of IFN responsive genes (left panel).  However, E1A then retasks 
the catalytically inactive hBre1 complex by using it as a scaffold to recruit hPaf1, leading 
to localized H3K4 and H3K79 trimethylation and stimulation of viral gene expression. 
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affect its transactivation ability.  Interestingly, HAdV 40 E1A exhibits a deficiency in 
activating transcription of other early viral genes during infection (Van Loon et al., 
1987), which could arise from its inability to productively utilize hBre1 to activate 
transcription. The interaction of HAdV 40 E1A with hBre1 may instead be primarily 
involved in perturbing the composition of the hBre1 complex to antagonize cellular IFN 
dependent gene expression, rather than enhancing E1A dependent transcriptional 
activation.  Interestingly, HAdV 12 E1A differs from all the other E1A proteins tested in 
that it did not bind to hBre1 and similarly showed no requirement for hBre1 or hPaf1 in 
transcriptional activation (Figure 3.11B).  The inability HAdV 12 E1A to bind hBre1 
would be predicted to lead to weaker transactivation, and this may explain why HAdV 12 
infection progresses more slowly and yields less virus compared to species C viruses, 
such as HAdV2/5 (Zhao et al., 2009).  In addition, HAdV 12 infection also differs from 
species C infection in that it is also less able to evade the type I IFN response (Zhao et al., 
2009), which would also be expected based on HAdV 12 E1A’s inability to bind hBre1. 
The region spanning residues 4-25 on E1A, which is required for interaction with 
hBre1 (Fonseca et al., 2012) and to recruit Paf1 to early gene promoters (Figure 3.7A), is 
also required for binding to the p300 and CBP acetyltransferases (Egan et al., 1988; 
Mymryk et al., 1992).  Both p300 and CBP are global cellular transcriptional regulators 
that function through their ability to acetylate proteins including histones and to recruit 
additional transcriptional regulators (Eckner et al., 1994; Ferrari et al., 2009, 2008; 
Horwitz et al., 2008b; Chen and Li, 2011; Bedford et al., 2010).  As mentioned above, 
p300 and CBP have documented roles in transcriptional regulation of viral early genes 
(Pelka et al., 2009b; Wong and Ziff, 1994).  It remains possible that the interaction of 
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E1A with p300/CBP may also assist hBre1 with the recruitment of hPaf1 or function 
independently to recruit hPaf1.  This is supported by a number of our observations.  
Firstly, knockdown of hBre1 does not completely abrogate hPaf1 recruitment to viral 
early genes (Figure 3.9B).  Secondly, an E1A mutant lacking residues 30-49, which binds 
to hBre1 but not p300/CBP, also exhibited reduced hPaf1 recruitment to HAdV early 
genes (Figure 3.7A).  This reduction was not as pronounced as for the Δ4-25 mutant, 
which binds neither hBre1 nor p300/CBP, supporting roles for both hBre1 and p300/CBP 
in hPaf1 recruitment.  Finally, knockdown of hPaf1 reduced viral early gene transcription 
to a greater extent than did knockdown of hBre1 (Figure 3.3 and 3.10A).  Taken together, 
these data suggest that one function of p300/CBP in early viral gene expression may be to 
assist hBre1 with the recruitment of hPaf1.  This could occur via direct interaction, 
alterations in chromatin acetylation that influence hPaf1 binding, or acetylation of other 
non-chromatin factors involved in hPaf1 recruitment.  Although both hBre1 and 
p300/CBP require residues 4-25 for interaction with E1A, p300/CBP also requires 
residues 36-69 for binding (Egan et al., 1988; Mymryk et al., 1992).  It remains to be 
determined if E1A can simultaneously interact with both hBre1 and p300/CBP, as has 
been shown for p300/CBP and pRb (Ferreon et al., 2009), or whether E1A interacts 
sequentially with these factors to prepare the local chromatin environment for efficient 
early viral gene expression. 
 Although no other viral proteins besides E1A have been shown to bind hBre1, 
several others target hPaf1.  Recently, hPaf1 was shown to bind the Influenza A H3N2 
NS1 protein (Marazzi et al., 2012).  This interaction provides a mechanism by which 
Influenza may block the IFN response (Marazzi et al., 2012), similarly to what we have 
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reported to result from the interaction of E1A with hBre1 (Fonseca et al., 2012). It is 
interesting that these very different viruses have independently evolved  to target the IFN 
response via these two interlocking epigenetic mechanisms.  In addition to Influenza 
NS1, the HIV gene product Tat also interacts with hPaf1 (Sobhian et al., 2010; Marazzi et 
al., 2012).  Tat recruits the hPaf1 complex along with numerous interacting partners to 
trimethylate H3K4 and activate viral gene expression from the HIV LTR (Sobhian et al., 
2010).  This is a very similar function to what we have observed with hPaf1 recruitment 
by E1A.  It remains possible that NS1 may also utilize its interaction with hPaf1 to 
regulate viral transcription in a manner similar to HAdV E1A and HIV Tat, but this has 
yet to be confirmed.  Correspondingly, the interaction of Tat with hPaf1 may also affect 
the type I IFN response.  Nevertheless, HAdV, Influenza A and HIV have convergently 
evolved to target the cellular hBre1/hPaf1 complexes as a strategy to regulate 
transcription during infection. The roles of these two complexes in the transcription 
process are clearly separable, as removal of hPaf1 dependent methylation patterns has 
similar effects on both cellular and viral genes, whereas hBre1 dependent 
monoubiquitination of H2B is required for IFN dependent transcription, but is 
unnecessary for E1A mediated activation of E2e, E3 and E4 gene expression.  How E1A 
compensates for the lack of active H2B monoubiquitination at the E2e, E3 and E4 
transcription units remains unknown, but may be related to differences between HAdV 
chromatin and normal cellular chromatin.   
In summary, we have determined that the interaction of E1A with hBre1 serves 
two completely different purposes during a HAdV infection (Figure 3.12).  E1A inhibits 
H2B monoubiquitination and suppresses the type I IFN response by disassociation of 
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hBre1 from Ube2b.  However, E1A then retasks the catalytically inactive hBre1 complex 
by using it as a scaffold to recruit hPaf1 and stimulate viral early gene expression.  
Achieving an inhibition of innate immunity, while simultaneously repurposing a target to 
enhance viral transcription, represents an elegant example of the incredible economy of 
action accomplished by a viral regulatory protein through a single protein interaction. 
 
3.4 Materials and Methods 
3.4.1 Cell lines and plasmids 
Human adenocarcinoma A549, human fibrosarcoma HT-1080, and human osteosarcoma 
U-2 OS cells were grown at 37oC with 5% CO2 in DMEM (Multicell) supplemented with 
10% fetal bovine serum (Gibco).  Plasmids were transfected into HT1080 and U-2 OS 
cells using Superfect reagent (Qiagen) following the manufacturer's recommendations.  
Transfection efficiency was typically, 70-80% for HT1080 and 40-50% for U-2 OS cell 
lines.  After 48 hours in culture, transfected cells were used for experimentation.  E1A’s 
from the HAdV types were cloned as fusions with GFP located at the C-terminus.  All 
E1A N-terminus and CR3 clones used in luciferase experiments were fused at their N-
terminus with the Gal4 DNA binding domain. 
 
3.4.2 Quantitative RT-PCR 
Total RNA was prepared with Trizol extraction (Invitrogen).  A total of 1μg of RNA was 
reverse transcribed into cDNA by random priming using the One step RT-PCR kit 
(Qiagen) following the manufacturers' instructions.  Quantification of cDNA was done  
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Table 3.1.  A List of Oligonucleotide Primers used in this chapter. 
Target Region Location Forward Reverse Size 
IFNβ1 Transcript 185-306 AGTGTCAGAAGCTCCTGTGGCAA TGCGGCGTCCTCCTTCTGGA 122 
IRF9 Transcript 902-1010 TTCCCCAAGCCTGGCCCACT GGCAAAGGCGCTGCACGAAG 109 
GAPDH Transcript 566-644 ACTGCTTAGCACCCCTGGCCAA ATGGCATGGACTGTGGTCATGAGTC 79 
E1A Transcript 1-207 ATGAGACATATTATCTGC TTAAGAGTCGGGAAAAATCTG 207 
E1B Transcript 1351-1474 GGTGCAGACCCTGCGAGT CGCGCTGAGTTTGGCTCTAG 123 
E2e Transcript 17-155 GGGGGTGGTTTCGCGCTGCTCC GCGGATGAGGCGGCGTATCGAG 138 
E2L Transcript 7345-7474 CTTGGAATACTCAGAGAG GCCATGCGCGGGCGGCAAGCG 129 
E3 Transcript 170-297 AGCTTTCTGAAATGTCCCGTCCGG CGAGGGCGGCTTTCGTCACAGGG 127 
E4 Transcript 1-328 ATGATTCGCTGCTTGAGGCTG TTATTCCAAAAGATTATCCAAAACCTC 329 
L5 Transcript 564-696 GGGCATTGACTTGAAAGAGCCC TTATTAATAGTCACACCTGG 132 
E1A Promoter 332-527 GCGCGTAATATTTGTCTAGGG GAAAACTCTACTCGCTGGC 195 
E1B Promoter 1546-1708 GGTGTAAACCTGTGATTGCG CAGATGTAACCAAGATTAGCCC 162 
E2e Promoter 7918-7793 ACGAGCTGCTTCCCAAAG ATGGCCTTGATGGACAGC 125 
E3 Promoter 27501-27633 TCTGAAATGTCCCGTCCGG GGCGGCTTTCGTCACAGGG 132 
E4 Promoter 35585-35694 
CAGCTCAATCAGTCACAGTGTAA
AAAGGGCC TGCGGTTTTCTGGGTGTTTT 110 
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using SYBR-Green Supermix for real-time qPCR (MyIQ, BioRAD) with oligonucleotide 
sequences that specifically recognize the indicated target.  GAPDH was used as a control 
for total cDNA.  Controls without reverse transcriptase were done for each RNA sample 
alongside the cDNA control.  Results were normalized to the GAPDH and uninfected 
sample.  The oligonucleotide sequences are listed in Supplementary Table S1. 
 
3.4.3 RNAi knockdown 
Downregulation of hBre1, RNF40, and hBre1 interacting proteins, including hPaf1 was 
performed using Silencer Select siRNA (Ambion).  siRNA was delivered to cells via 
transfection with Silentfect (BioRad) following the manufacturer’s instructions: 3 hours 
after seeding cells, for a period of 48 hours.  A scrambled siRNA was used as a control. 
 
3.4.4 Virus infection of cells 
All viruses are derived from the HAdV 5 dl309 background (Jones and Shenk, 1979) and 
express both the larger 289Rand smaller 243R E1A proteins (Egan et al., 1988).  Cells 
were infected with WT (dl309), or a panel of HAdV containing the indicated E1A 
deletion mutations: ΔE1A (dl312), E1A Δ4-25 (dl1101), E1A Δ26-35 (dl1102), E1A 
Δ30-49 (dl1103).  HAdV was used at a multiplicity of infection (MOI) of 5 pfu/cell.  Cell 
cultures were infected at 50% confluence and left for 20 hours.  Virus infection was 
found to be near 100% by fluorescence microscopy under these conditions using virus 
expressing GFP.  Subconfluent cells were collected for further experimentation. 
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Table 3.2.  A List of Antibodies used in this chapter. 
Reactivity Description Company Cat # 
Mouse IgG Rabbit polyclonal Sigma M-7023 
Actin Rabbit polyclonal Sigma A 2066 
GFP Rabbit polyclonal Clonetech 632592 
hPaf1 Rabbit polyclonal Bethyl Labs A300-173A 
H2B Rabbit polyclonal Millipore 07-371 
H2BK120-monoubiquitination Mouse monoclonal Millipore 05-1312 
H3K4 tri methylation Mouse monoclonal Abcam Ab1012 
H3K18 acetylation Rabbit polyclonal Abcam Ab1191 
H3K79 tri methylation Rabbit polyclonal Abcam Ab2621 
hBre1/RNF20 Mouse monoclonal Sigma R8904 
M73 (E1A) Mouse monoclonal In house  
RNA Pol II Rabbit polyclonal Abcam Ab26721 
RNF40/hBre1b/RBP95 Mouse monoclonal Sigma R9029 
Ube2b/hRad6 Rabbit polyclonal Bethyl Labs A300-281A 
9C12 (hexon) Mouse monoclonal DSHB TC31-9C12.C9 
27F11 (hexon) Mouse monoclonal DSHB TC31-27F11.C2 
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3.4.5 Gal4 Luciferase assay 
Cells were transfected with a β-galactosidase reporter plasmid for normalization, a 
plasmid containing the luciferase gene driven by a 6xGal4 binding sequence, and the 
indicated Gal4 DNA binding domain fusion plasmids.  After 48 hours, cells were lysed in 
200μL using the supplied lysis buffer (Promega E397A).  For detection of luciferase 
production, 50μL of lysate was mixed with 50uL of Luciferase Substrate (Promega 
E151A) immediately before detection of light as measured using a Berthold Lumat LB 
9507.  Results were then set to an empty plasmid control and further normalized via β-
galactosidase activity as detected by ONPG (Bioshop) assays.   
 
3.4.6 Western blotting and co-immunoprecipitation 
Cells were lysed with NP40 lysis buffer (150mM NaCl, 50mM Tris-HCl pH 7.5, 0.1% 
NP-40) and protein concentrations were determined with BioRad protein assay reagent 
using BSA as a standard.  0.5mg of protein lysate was immunoprecipitated with 1 µg of 
GFP rabbit polyclonal (Supp. Table 2) at 4oC for 4 hours.  25 µg of protein was kept as 
5% input, except as noted in the Figure legend of individual blots.  After 3 washes in 
NP40 lysis buffer, complexes were boiled in 25 µL of sample buffer for 5 min.  Proteins 
were separated on NuPage 4-12% Bis-Tris gradient gels (Invitrogen) and transferred onto 
a nitrocellulose membrane (Amersham).  Membranes were blocked in TBS with 0.1% 
Tween-20 and 5% skim milk or BSA and blotted with the indicated primary overnight at 
4oC.  Details for the primary antibodies may be found in Table S2.  Horseradish 
peroxidase conjugated secondary antibodies were detected using ECL Plus western 
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blotting detection system (Amersham). 
 
3.4.7 Chromatin immunoprecipitation (ChIP) and ChIP-reChIP assays 
Approximately 107 cells per sample were cross-linked with 1% formaldehyde at room 
temperature for 10 min.  Cells were washed twice with ice cold PBS and harvested. Cell 
pellets were lysed in 1mL of cell lysis buffer (50 mM Tris-HCl [pH8.1], 10 mM EDTA, 
1% SDS, and a protease inhibitor cocktail (Sigma) on ice for 10 min.  Lysates were 
sonicated in an ultrasonic biorupter bath (Diogenode XL-2006 TO) to yield DNA 
fragment sizes of 200-500 base pairs.  Samples were then centrifuged at 10,000xg for 10 
min.  1 mg of protein was used for ChIP, 100 μg of this was kept as 5% input.  
Supernatants were then diluted 10-fold in dilution buffer (20 mM Tris-HCl [pH8.1], 1% 
Triton X-100, 2 mM EDTA, 150mM NaCl and protease inhibitors) and precleared with 
50 μL of ChIP protein-A Sepharose (50% slurry of protein A-Sepharose containing 2.5 
μg of salmon sperm DNA and BSA /mL) for 50 min at 4oC.  Immunoprecipitations were 
performed overnight at 4oC using 5 μg of the indicated antibody found in Supp. Table 2.  
The next morning, 50 μL of ChIP protein-A Sepharose was incubated with each sample 
for 2 hrs.  Beads were then washed once each with 500 μL of wash buffer 1 (0.1% SDS, 
1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH8.1, 150 mM NaCl), wash buffer II 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH8.1, 500 mM NaCl), 
and wash buffer III (0.25 M LiCl, 1% NP-40, 1% Na-deoxycholate, 1 mM EDTA, 10 
mM Tris-HCl pH8.0) respectively and then washed twice with Tris-EDTA buffer.  
Immunocomplexes were extracted twice with 150 μL of elution buffer (1% SDS, 0.1 M 
NaHCO3).  For ChIP-reChIP, samples were then rediluted 10x with dilution buffer and 
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immunoprecipitation was repeated with a second antibody as indicated.  After final 
elution, 12 μL of 5M NaCl was added to the 300 μL pooled elution and incubated at 65oC 
overnight to decrosslink the complexes.  DNA was then purified using Quigen PCR 
Purification Spin Columns.  Conditions for qRT PCR using SYBR Green were as per the 
manufacturers' directions.  Briefly, each 15 μL reaction contained 80 nM oligos and 0.5 
uL of ChIP DNA. 
 
3.4.8 Statistical analysis 
All experiments were carried out in duplicate with three replicates, with the exception of 
those shown in Figure 3.2 and Figure 3.9.   Figure 3.2 and Figure 3.9 were carried out in 
duplicate with two replicates. Graphs represent the mean and standard error of the mean 
(S.E.M) of all experiments, while western blots are representative experiments. All 
numerical values represent means + S.E.M.  For blots, a representative example of the 
replicates is shown.  Statistical significance of the differences was calculated using one 
way ANOVA and a Holm-Sidak post-hoc comparison to all other treatments in the 
experiment. 
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Chapter 4:  
Discussion 
4.1 Thesis Summary 
This thesis describes my studies of the HAdV E1A protein.  Specifically, I describe the 
interaction of the N-terminus of E1A with the cellular E3 ubiquitin ligase hBre1 and the 
consequences thereof.  In chapter 2, hBre1 was shown to monoubiquitinate H2B 
throughout the transcribed region of ISGs after stimulation of the innate immune 
response by IFN treatment or infection with defective virus (Figure 2.1).  The 
monoubiquination of H2B was so highly upregulated by these stimuli, that large changes 
in the global levels of H2B-ub were easily detectable by western blot analysis (Figure 
2.1).  I showed that H2B-ub was required for transcriptional activation of a panel of ISGs 
(Figure 2.3).  Further, introduction of E1A into the system resulted in global reductions in 
H2B-ub (Figure 2.4).  I showed that this was a result of E1A binding hBre1 and blocking 
the recruitment of the E2 conjugase of the hBre1 complex, Ube2b, to ISG gene bodies 
(Figures 2.7, 2.9).  This inability to properly recruit Ube2b resulted in a parallel reduction 
of H2B-ub at ISGs and corresponding decreases in ISG transcription, dampening the IFN 
response and enhancing virus growth (Figure 2.12).  In chapter 3, I observed that hBre1 
was also recruited to the viral genome by E1A and plays a role in early viral 
transcription.  My initial experiments using a Gal4-E1A fusion with a luciferase reporter 
system showed a requirement for hBre1 in E1A dependent transcriptional activation 
(Figure 3.1).  From here, I observed both a localization of hBre1 on the promoters of 
several HAdV early genes as well as a requirement for hBre1 in the transcriptional 
173 
 
activation of these early genes during infection (Figures 3.3, 3.4).  As E1A disrupts the 
catalytic activity of the hBre1 complex in the context of cellular chromatin (Figure 2.7, 
2.9) and recruitment of hBre1 to viral chromatin is not accompanied by H2B-ub (Figure 
3.5), it appeared that the Bre1 complex was not functioning directly to modify viral 
chromatin.  Instead, I hypothesized that hBre1, in the absence of its well characterized 
activity, may function in this context as a scaffold to make interactions with other cellular 
transcriptional activators.  I tested the requirement of known hBre1 interacting proteins 
for their effects on E1A dependent transactivation in the Gal4-E1A fusion luciferase 
system.  I discovered that E1A uses hBre1 to recruit the hPaf1 complex to viral genes for 
transactivation (Figure 3.6).  A reduction in transcription of viral early genes by hPaf1 
knockdown was observed with concomitant reduction in several hPaf1 linked hPTMs, 
including H3K4me3 and H3K79me3 (Figure 3.10).  Overall, my results have uncovered a 
novel subset of genes affected by H2B-ub and hBre1, as well as a novel mechanism by 
which E1A rewires the cellular network by retasking cellular transcriptional regulatory 
proteins (Figures 2.14, 3.12). 
 
4.2 The interaction between E1A and hBre1 
Yeast Bre1 (yBre1) was originally identified through a susceptibility screen for Brefeldin 
A, a drug that inhibits transport of proteins from ER to Golgi (Murén et al., 2001).  Later, 
in 2003, yBre1 was identified as an E3 ubiquitin RING ligase that recruits an E2 
conjugase, Rad6 (yeast Ube2b homologue), to cellular chromatin.  Along with the 
accessory factor Lge1, yBre1 and Rad6 are involved in the monoubiquitination of H2B at 
K123 in yeast (K120 in mammals) (Wood et al., 2003; Hwang et al., 2003).  Building on 
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the work published in these seminal yeast papers, this complex was further characterized 
and the homologous mammalian complex was identified.  The mammalian complex, is 
comprised of hBre1/RNF20, RNF40/RBP95, Rad6A&B/Ube2A&B and the understudied 
WAC1 subunit.  The hBre1 complex does not appear to function at all transcribed genes, 
but instead has been reported to catalyze the formation of H2B-ub on several distinct 
gene sets (Kim et al., 2005, 2009; Zhang and Yu, 2011).  These include genes regulated 
by p53, MLL, HOX, Notch and estrogen receptor transcription factors, as well as directly 
influencing important cellular processes such as the DNA damage response and stem cell 
differentiation (Moyal et al., 2011; Bray et al., 2005; Mohan et al., 2010; Nakamura et al., 
2011; Prenzel et al., 2011; Shema et al., 2008; Zhu et al., 2005; Chen et al., 2012; 
Karpiuk et al., 2012; Wang et al., 2013).  In essence, hBre1 is required for the efficient 
transcription of a very specific subset of highly important cellular genes, many of which 
are highly relevant to cancer.  As such, the targeting of hBre1 by a viral oncoprotein like 
E1A is perhaps not unexpected. 
 The N-terminal region of E1A was found to interact with yBre1 in a yeast 2-
hybrid library screen (Appendix Figure 4.11).  This interaction was further confirmed 
with hBre1 in mammalian co-immunoprecipitation experiments (Figures 2.7, 2.8).  Using 
a panel of well characterized E1A deletion mutants, hBre1 was shown to interact with 
E1A through residues 4-25.  Binding did not require the adjacent region, as seen by its 
ability to interact with E1A containing deletions of residues 26-35 and 30-49 (Figure 2.7, 
2.8).  Importantly, this pattern of interaction differentiates the hBre1 interaction from 
other well defined E1A interactors, such as p300/CBP (Figure 2.4).  The same interaction 
profile was seen for the RNF40 component of the hBre1 complex.  RNF40 is an 
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orthologue of hBre1, and the two proteins share 57% identity and 72% similarity (Figure 
4.1).  Considering this, the interaction surface on E1A could potentially directly bind one 
or both of these proteins.  However, studies of co-precipitation using purified protein will 
have to be performed to conclusively determine which is directly targeted by E1A. 
 Of particular interest, the mechanism by which E1A blocks the interaction 
between the hBre1/RNF40 and Ube2b subunits of the hBre1 complex remains to be 
determined.  The most probable explanation is direct steric hindrance via a competition 
between E1A and Ube2b for interaction with hBre1.  The interaction between 
hBre1/RNF40 and Ube2b has been mapped to between residues 230 and 381 of hBre1 
(Kim et al., 2009).  Going forward, it will be important to determine the interaction site 
on hBre1 utilized by E1A and further map the Ube2b binding sites on hBre1.  Other 
possible explanations for the ability of E1A to block Ube2b association with hBre1 
include a change in conformation as a result of E1A binding to hBre1 or indirect steric 
hindrance by the large multi-protein complexes with which E1A may be associated with 
(Figure 4.2). 
 
4.3 The modulation of IFN signaling by E1A 
E1A has previously been shown to block the IFN response (Anderson and Fennie, 1987; 
Kalvakolanu et al., 1991; Reich et al., 1988).  In my studies, I have uncovered a novel 
hPTM based mechanism which serves to block ISG transcription.  The interaction of E1A 
with the hBre1 complex inhibits H2B-ub by disrupting the catalytic activity of the hBre1 
complex (Figure 2.14).  However, other papers have implicated effects of E1A on 
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Figure 4.1.  Alignment of hBre1/RNF20 and RNF40.  Sequence alignment shows 57% 
identity and 72% similarity using Blosum 35 score tables.  Sequence identity is indicated 
by black shading, while sequence similarity in the absence of identity is indicated by grey 
shading.  
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 p300/CBP, Stat1 and reductions in expression/activity of trans-acting factors necessary 
for the phosphorylation events preceding the formation of ISGF3 (Leonard and Sen, 
1996; Look et al., 1998; Zhang et al., 1996; Bhattacharya et al., 1996).  It should be noted 
that these papers all attribute the ability to downregulate IFN signaling to the E1A Δ4-25 
deletion mutant.  In addition, this work is generally correlative, without showing direct 
evidence of p300/CBP or Stat1 involvement.  Further, they analyze signaling by type II 
IFN (gamma or gamma associated site genes) rather than type I IFN, which are mostly 
non-overlapping gene sets with different transcriptional regulation (Samarajiwa et al., 
2009; Rusinova et al., 2013).  Lastly, another publication has shown that p300/CBP, as 
well as the H3K18ac hPTM which these proteins catalyze, is found at type I IFN genes 
before stimulation (Escoubet-Lozach et al., 2011).  This is thought to be a preactivation 
mechanism that allows for faster initiation and, ultimately, faster production of an 
antiviral state.  However, p300 was not found to have been displaced from type I IFN 
genes until after the repression of these genes by virus infection, noted as "Class I" in 
these studies (Horwitz et al., 2008b; Ferrari et al., 2009).  These data suggest that, 
although blocking p300/CBP and Stat1 may play a role in the repression of ISGs during 
HAdV infection, interference with their function by HAdV may not necessarily be 
sufficient to block IFN response.  As such, our observation that the interaction of E1A 
with hBre1 blocks ISG transcription is not contradicted by previously published data. 
Indeed, antagonism of H2B-ub by E1A may cooperate with the mechanisms proposed in 
those studies to provide a more complete understanding of what is actually occurring 
during infection.  In fact, the possibility remains that these are interconnected modalities 
of ISG suppression by HAdV.  As the mechanism by which the hBre1 complex and Stat1 
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Figure 4.2.  Possible mechanisms by which E1A blocks the hBre1 interaction with 
Ube2b.  (A)  Under normal conditions, Ube2b is able to bind hBre1 between residues 230 
and 381 (white on hBre1).  However, this is blocked in the presence of E1A.  The 
possible mechanisms which may attribute this result could include (B) direct steric 
hindrance, whereby E1A competes for the same binding surface as Ube2b, (C) the 
binding of E1A causes a conformational change, altering the binding site for Ube2b on 
hBre1 in such a way that Ube2b can no longer interact, or (D) indirect steric hindrance 
where E1A binds to a different site on hBre1 from Ube2b, but masks the Ube2b binding 
site due to the recruitment of large E1A interacting complexes. 
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are recruited to ISGs remains unclear, it is possible that these complexes interact and are 
recruited together to ISGs.  What is clear in these separate studies is that Stat1, p300, and 
the hBre1 complex are all required for efficient ISG transcription.  Going forward, even 
more detailed studies of transcriptional control of ISGs will remain an important avenue 
of research.  These may allow a reactivation of a suppressed IFN response that will help 
clear a serious infection or help limit an overactive life threatening IFN response. 
 
4.4 hPaf1 interaction with hBre1 
Previous work has established an interaction between hBre1 and the hPaf1 complex (Kim 
and Roeder, 2009).  This interaction is necessary for H2B-ub by the hBre1 complex as 
well as H3K4me3 and K79me3, which are induced by hPaf1 through the MLL/SET1 and 
DOT1 complexes (Figure 1.7) (Kim and Roeder, 2009; Marazzi et al., 2012; Wood et al., 
2003).  It has been found that the hBre1 complex co-precipitates with the full hPaf1 
complex in in vitro and ex vivo cell culture models through an interaction with hPaf1 
(Kim et al., 2009; Kim and Roeder, 2009; Wood et al., 2003; Mulder et al., 2007).  In 
yeast, only the histone modification domain of the Rtf1 component of the hPaf1 complex 
has been shown necessary for all of these hPTM effects (Tomson and Arndt, 2012).  
Interestingly, this effect is independent of the Rtf1 DNA binding domain.  In fact, 
removal of the DNA binding domain causes non-specific hPTM induced activation of 
genes (Piro et al., 2012).  This may suggest that the hPaf1 complex is a controller of 
H2B-ub, H3K4me3 and K79me3 through regulating the hBre1 complex or via 
scaffolding of these genetically interacting complexes.  We have found that hBre1 is able 
to, in the absence of Ube2b, recruit the hPaf1 complex to virus early genes (Figures 3.7, 
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3.9, 3.10).  Given these previously stated findings, the hBre1 interaction with Rtf1, 
through hPaf1, may operate independently of H2B-ub to recruit the MLL/SET1 and 
DOT1 complexes.  Recruitment could, in turn, lead to the local generation of the 
respective hPTMs created by these complexes. To confirm this model, future work 
demonstrating that recruitment of the hPaf1 complex member, Rtf1, by E1A is essential 
for the observed hPTMs induced on the viral genome would be necessary. 
   These results do not, however, explain the lack of hPaf1 recruitment to cellular 
ISGs in the presence of E1A.  Under inducing conditions, hBre1 was found to be 
associated with ISGs and this resulted in H2B-ub throughout the gene body and 
H3K4me3 and H3K79me3 on the gene promoter (Figure 2.3).  In contrast, during viral 
infection, E1A was able to block these hPTMs by disrupting the hBre1 complex.  
However, it should be noted that hBre1 is still present at ISGs, co-localizing with E1A 
Figure 2.9).  Considering the interaction of the hBre1 complex with hPaf1 and the 
localization to ISGs, I expected that hPaf1 would be recruited to ISGs and be able to 
perform its activating functions with hBre1.  This is, however, clearly not seen (Figure 
3.8).  In the context of cellular ISGs, hPaf1 is, along with Ube2b, specifically blocked 
from association with ISGs in the presence of E1A.  No mechanistic evidence exists to 
explain this finding.  It is possible that there may be a difference in the 3-dimensional 
loading of the hBre1 and E1A proteins on the ISG and viral chromatin that accounts for 
this difference.  As hBre1 is found on ISGs in the absence of E1A, it would seem prudent 
to assume that hBre1 loads onto the chromatin first in this context and that E1A targets 
hBre1 bound at ISGs.  In contrast, on the viral chromatin, hBre1 is not present in the 
absence of E1A.  Indeed, hBre1 appears to be recruited by E1A to viral chromatin.  The 
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altered order of recruitment between these two sets of hBre1 regulated genes suggests 
that in the context of cellular chromatin, hBre1 may not be completely exposed to the 
cellular environment due to being coated by E1A and its associated complexes.  
However, in the context of viral genes, E1A may be proximal to the viral chromatin, with 
hBre1 placed in a more exposed location that allows for interaction with the hPaf1 
complex. 
 Future functional studies of the roles of the hPaf1 complex in viral transcription 
will need to also focus on the means of regulation by the hPaf1 complex.  My data shows 
a positive effect on general transcription by hPaf1 recruitment.  However, the hPaf1 
complex is involved in several stages of transcriptional control, including transcriptional 
initiation and elongation (Jaehning, 2010).  This leaves four distinct possibilities for the 
mechanism behind the positive influence of the hPaf1 complex in viral early gene 
transcription: increased transcriptional initiation, more efficient elongation, a 
combination of both initiation and elongation or through transcriptionally independent 
processes such as altered mRNA processing. 
 
4.5 E1A control of viral early gene transcription 
HAdV E1A mediated control of transcription has been historically used as a paradigm of 
transcriptional activation of cellular genes.  E1A contains two regions that independently 
function as transcriptional activation domains when fused to a heterologous DNA binding 
domain: the N-terminus and CR3.  Although the N-terminus of E1A contains a 
transactivation domain, CR3 is considered to be the primary transactivation domain.  
Formation of the transcriptional activation complex by E1A CR3 includes binding of 
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activation factors including mediator and TBP and modulators of transcription including 
the acetyltransferases Gcn5 and pCaf, the proteasome and other transcription factors 
(Geisberg et al., 1994; Boyer et al., 1999; Stevens et al., 2002; Webster and Ricciardi, 
1991; Ablack et al., 2010, 2012; Rasti et al., 2006).  These allow for transcriptional 
activation and modulation for optimal levels of target gene transcription.  As well, the N-
terminus assists CR3 in recruiting some of these factors, as in the case of p300/CBP, 
pCaf, and TBP (Pelka et al., 2009b, 2008; Frisch and Mymryk, 2002).  E1A also 
associates with many other transcriptional regulators.  Indeed, targets of several regions 
of E1A may be used for localizing the E1A associated transcriptional machinery to 
cellular chromatin for modulating expression of specific groups of genes.  These include 
p300 and pRb which are targeted by the N-terminus and CR2 respectively (Horwitz et al., 
2008b; Ferrari et al., 2009).  It has been hypothesized that E1A uses these cellular 
proteins as landmarks to target regions where activation states need to be changed.  In the 
case of pRb, E1A targets repressed cell cycle regulatory genes for activation.  In the case 
of p300/CBP, E1A targets activated differentiation specific genes for repression (Horwitz 
et al., 2008b; Ferrari et al., 2009).  A similar situation has been reported for the E1A 
target CtBP.  E1A targets the CtBP co-repressor through CR4 and blocks the repressive 
effects of CtBP at these genes (Johansson et al., 2005; Zhao et al., 2006).  Then, in 
association with a second CtBP interaction found within CR3, E1A can induce CtBP 
target genes by recruiting cellular activation machinery for further activation of these 
initially repressed genes (Bruton et al., 2008).  The mechanisms by which E1A modulates 
cellular gene transcription are still not fully developed, but are being actively pursued by 
multiple groups of investigators. 
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 Regulation of transcription from the E1A gene itself is well characterized.  As 
E1A is produced immediately after viral DNA is transported into the nucleus, the initial 
stage of E1A transcription occurs in the absence of virally encoded transactivators and 
relies on cellular cis acting factors on the viral DNA (Hearing and Shenk, 1983, 1986).  
This initial level of transcription from the E1A gene is augmented by E1A itself, in a 
positive feedback loop.  E1A then similarly activates the other viral early genes. 
 Despite the plethora of research on E1A mediated transcription, little is known as 
to how E1A specifically activates viral transcription.  Multiple studies have shown that 
this is a dynamic and complex process, which appears to be carefully orchestrated and 
involves many factors.  Early results showed that regulation of HAdV early genes may 
not be through a single mechanism.  As one specific example, the HAdV5 host range 440 
mutant (lacking E1A Δ141-289) is able to activate the E1B and E4 transcripts to wildtype 
levels, however, the E2 and E3 transcripts were not detectable (Solnick, 1981). Despite 
previous findings showing that E1A is readily detectable by ChIP analysis at all viral 
early genes (Rasti et al., 2006), each is differentially affected by E1A mediated 
transcriptional activation (Figures 3.3, 3.4, 3.7, 3.10).  As such, viral early genes are 
individually regulated in a very context dependent manner.  This is similar to the 
observation by the labs of Berk and Kurdistani, which found that E1A modulates 
transcription of cellular genes in many ways, and demonstrated that these can be broadly 
grouped into three categories based on temporal changes in expression and occupancy by 
E1A (Horwitz et al., 2008b; Ferrari et al., 2009).  It seems that the E1A complexes at 
each viral early gene are not equivalent and this may be a result from different 
combinations of cis-acting elements at HAdV early genes.  These may affect 
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transcription by either assisting in the recruitment of factors directly or in co-operation 
with E1A.  Previous data has shown that the E3 and E4 genes are differentially affected 
in the absence of p300/CBP recruitment (Pelka et al., 2009b).  Indeed, my studies of the 
role of hBre1 in regulating expression from viral early genes shows similar results.  
Specifically, hBre1 knockdown drastically reduces E4 expression (15% of wt), only 
moderately reduces E3 (57% of wt) and has no statistical effect on E1A (95% of wt) 
(Figure 3.1).  This provides further evidence that E1A differentially regulates early gene 
expression via a variety of distinct mechanisms.  Similar results can be seen for 
endogenous cellular transcriptional regulators.  As one example, ZNF217 can activate or 
repress gene expression in a context dependent manner.  In most cases, ZNF217 represses 
transcription by recruiting repressive complexes such as CoREST to actively methylate 
DNA CpG islands (Thillainadesan et al., 2012) and LSD1 to demethylate H3K4me3, 
which is an activating hPMTs (Murray-Stewart et al., 2013; Musri et al., 2010).  
However, ZNF217 may also participate in transcriptional activation by recruiting 
CoREST and LSD1 to demethylate H3K9me3 and H3K56me3, which are repressive 
hPTMs (Musri et al., 2010; Sakane et al., 2011).  Indeed, HIV Tat recruits ZNF217 and 
LSD1 for the purpose of transcriptional activation by demethylating H3K51 
monomethylation at viral LTRs (Sakane et al., 2011).  Similarly to E1A modulation of 
hBre1 and hPaf1, the context dependent activation or repression functions of ZNF217 are 
not well understood.  Overall, transcriptional activation of viral genes by E1A may 
provide a useful model of non-static, context dependent transcriptional activation in 
which hPTMs and cis acting factors regulate transcriptional complexes. 
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4.6 E1A control of cellular transcription 
As described above, a significant amount of research has been applied to study the 
function of E1A on cellular transcription.  A seminal set of papers published by the 
laboratories of Drs. Berk and Kurdistani have placed the mechanistic implications of 
p300 and pRb binding by E1A into a global context using ChIP and cDNA microarray 
experiments (Horwitz et al., 2008b; Ferrari et al., 2009).  Despite the intensive 
characterization of these interactions in these and other publications, including structural 
interaction data (Pelka et al., 2009b; Whyte et al., 1988; Loewenstein et al., 2012; 
Kadeppagari et al., 2009; Ferreon et al., 2009), and their importance in E1A mediated 
transcriptional control, no perfectly generalizable global effect was observed.  Instead, 
genes were categorized into classes dependent on their temporal patterns of activation or 
repression of transcription.  However, the initial activation state of a given gene did not 
necessarily correlate with transcriptional outcomes, as some inactive genes were left 
inactive and some active genes were left active.  Further, many cellular genes repressed 
by pRb prior to infection remained repressed despite E1A recruitment.  Similarly, many 
genes which were transcriptionally activated by p300/CBP before infection remained 
active post infection despite E1A localization.  These results clearly indicate that E1A 
does not simply function to alter the state of transcription on the cellular chromatin by 
overriding all aspects of regulation.  Similarly to viral chromatin, the effects of E1A 
appear context dependent, likely being differentially regulated by cellular cis elements 
and transacting factors.  The most probable situation is that E1A is able to globally 
modify the transcriptional state of cellular genes, while being further regulated, 
biochemically and genetically, by context dependent interactions with cellular and viral 
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proteins.  This would put specific subsets of genes into a more controlled context, which 
would better benefit viral infection.  As such, although p300/CBP and pRb may be 
general factors with which E1A alters global cellular transcriptional profiles, other 
interacting proteins may help to modulate these activities on specifically targeted gene 
sets.  This would lead to the exquisite and reproducible control of cellular transcription 
despite infection of a wide range of cell types with different cellular milieus and growth 
conditions.  Further, this suggests that additional study of the more transient or less 
globally affected targets of E1A may provide insight into the complex control of cellular 
transcription in which these proteins participate. 
 
4.7 Significance of this Research 
An important driver in research is often the satisfaction of the innate human need for 
discovery, knowledge and answers to new, previously unanswered questions.  
Importantly, in a societal context, these discoveries should, and often will, lead to 
improvements in the human condition and positive life outcomes.  My data has provided 
insight into the cellular activities of both the hBre1 complex as well as the hPaf1 
complex.  Further, they have provided valuable understanding of the requirement for 
hBre1 in E1A mediated evasion of the IFN response and transcriptional activation of 
viral early gene transcription.  More abstractly, this study underlines the vast wealth of 
undiscovered knowledge with which HAdV may be a useful tool in probing the 
complexities of transcriptional control.  As well, my work exposes new aspects of 
cellular transcriptional control and reveals how immature our grasp is of the intricacies of 
some important aspects of cellular gene expression.  Moving forward, a deeper 
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understanding of cellular processes including cellular transcription will allow for more 
discrete and directed manipulation of physiological and cellular activity in the treatment 
of disease.  Furthermore, it would seem that HAdV and E1A still have much more 
information to share with us in our goal to further our knowledge of biological science.  
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Appendices 
Appendix 1. BLAST results for yeast 2-hybrid sequencing data for extracted clones S1 
and S4.  Positive results from yeast 2-hybrid library screen of the yeast genome were 
picked and plasmids were purified and sequenced.  BLAST results showed that clones S1 
and S4 were identical copies of yBre1. 
S1+S4 – BRE1 forward in frame   
CHR4|NC_001136| [org=Saccharomyces cerevisiae] [strain=S288C] [moltype=genomic] [chromosome=IV]  Length = 1,531,916 
 
  Minus Strand HSPs: 
 
 Score = 3120 (474.2 bits), Expect = 8.7e-136, P = 8.7e-136  [Retrieve Sequence / ORF Map 
/ SGD GBROWSE] 
 Identities = 630/645 (97%), Positives = 630/645 (97%), Strand = Minus / Plus 
 
Query:    863 GATGTATTATCACCATTAATTGCAGAGGAGTCTTTATTTCCAGATTTTATATTGTTTTCA 804 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 325464 GATGTATTATCACCATTAATTGCAGAGGAGTCTTTATTTCCAGATTTTATATTGTTTTCA 325523 
 
Query:    803 TTAGATTCTTTTTCATCTTCCCGTAATTCCTTTACAGCATCAGTCTTATCTTCCTTAAAA 744 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 325524 TTAGATTCTTTTTCATCTTCCCGTAATTCCTTTACAGCATCAGTCTTATCTTCCTTAAAA 325583 
 
Query:    743 ACACGTTTTATAGTAAAGGATTCATCTCTATCATACTTGCGAATTATATTTGTATAATAT 684 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 325584 ACACGTTTTATAGTAAAGGATTCATCTCTATCATACTTGCGAATTATATTTGTATAATAT 325643 
 
Query:    683 TCCTTCAAAGCAGAAATCTCCTCTGTCAATTGCGAATTTTCATAAAAGAGCTCCTCTTTA 624 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 325644 TCCTTCAAAGCAGAAATCTCCTCTGTCAATTGCGAATTTTCATAAAAGAGCTCCTCTTTA 325703 
 
Query:    623 CTTTTCCGCAAGTTTTTTAACTCCGTTGTTAATTCTTGAATATGATCCGAAGCATTACTA 564 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 325704 CTTTTCCGCAAGTTTTTTAACTCCGTTGTTAATTCTTGAATATGATCCGAAGCATTACTA 325763 
 
Query:    563 TTAGTATTACTATCTGTCGTGTTTGGCTTCCCATATTTAGTCAGTAGCTTCATGAAAGAA 504 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 325764 TTAGTATTACTATCTGTCGTGTTTGGCTTCCCATATTTAGTCAGTAGCTTCATGAAAGAA 325823 
 
Query:    503 TCACTGCGCTGAACTATCAACGTCTCATCGCCTTGGGCTATTTCCCTACATAGTTGCTTC 444 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 325824 TCACTGCGCTGAACTATCAACGTCTCATCGCCTTGGGCTATTTCCCTACATAGTTGCTTC 325883 
 
Query:    443 TCGTTGGCGTCTGTGCAGAATGNTTCGATAAACCTAGCTAAAGTTACTATCAGCGCCATA 384 
              |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||| 
Sbjct: 325884 TCGTTGGCGTCTGTGCAGAATGTTTCGATAAACCTAGCTAAAGTTACTATCAGCGCCATA 325943 
 
Query:    383 ATATTTGCCAACTTGCGGGAAACATCTATGCACTCCCTTCTTGAAAGTTCATATTGCTTT 324 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 325944 ATATTTGCCAACTTGCGGGAAACATCTATGCACTCCCTTCTTGAAAGTTCATATTGCTTT 326003 
 
Query:    323 CGCANGGCTTCAAAGTCGACTCNTCGACGATTTATACNTCTAAACAAAGCTTCTTTTTGA 264 
              |||| ||||||||||||||||| |||||||||||||| |||||||||||||||||||||| 
Sbjct: 326004 CGCAAGGCTTCAAAGTCGACTCTTCGACGATTTATACATCTAAACAAAGCTTCTTTTTGA 326063 
 
Query:    263 AACGCTATCNNNTCNNATTGAGTAANCNGNTCNNTNGGATCGCTT 219 
              |||||||||   ||  ||||||||| | | ||  | ||||||||| 
Sbjct: 326064 AACGCTATCACATCAGATTGAGTAAGCGGTTCACTAGGATCGCTT 326108  
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Queen Elizabeth II Graduate Scholarship in Science and Technology, Ontario Student 
Assistance Program, Canada, Effective: 05/2011, Ending: 04/2012, $15,000 
Ontario Graduate Scholarship, Ontario Student Assistance Program, Canada, Effective: 
05/2010, Ending: 04/2011, $15,000 
Ontario Graduate Scholarship, Ontario Student Assistance Program, Canada, Effective: 
05/2009, Ending: 04/2010, $15,000 
Ontario Graduate Scholarship in Science and Technology, Ontario Student Assistance 
Program, Canada, Effective: 05/2008, Ending: 04/2009, $15,000 
 
Scholarships (Internal): 
 
Schulich Graduate Scholarship, Schulich School of Medicine and Dentistry, Canada, 
Effective: 09/2011, Ending: 08/2012, $7,204 
Schulich Graduate Scholarship, Schulich School of Medicine and Dentistry, Canada, 
Effective: 09/2010, Ending: 08/2011, $7,204 
Schulich Graduate Scholarship, Schulich School of Medicine and Dentistry, Canada, 
Effective: 09/2009, Ending: 08/2010, $6,672 
Schulich Graduate Scholarship, Schulich School of Medicine and Dentistry, Canada, 
Effective: 09/2008, Ending: 08/2009, $6,672 
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Schulich Graduate Enhancement Scholarship, Schulich School of Medicine and 
Dentistry, Canada, Effective: 09/2007, Ending: 08/2009, $10,000 
Schulich Graduate Scholarship, Schulich School of Medicine and Dentistry, Canada, 
Effective: 09/2007, Ending: 08/2008, $6,672 
 
Scholarships (Travel Awards): 
 
London Health Research Day platform presentation award: $600. 
Graduate Student Travel Award from the Division of Experimental Oncology: $1,500. 
26th Annual Canadian Student Research Forum.:  ~1000. 
 
Teaching Experience 
 
September 2011 –December 2011 
Graduate Teaching Assistant for Microbiology and Immunology 2100A 
September 2009-December 2009 
Graduate Teaching Assistant for Microbiology and Immunology 2100A 
 
